

chain nodes :
7 9 11 12 13 14
ring nodes :
1 2 3 4 5 6 15 16 17 18 19 20
chain bonds :
2-13 9-11 9-12 13-14 14-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
exact/norm bonds :
2-13 9-11 9-12 13-14 14-19 15-16 15-20 16-17 17-18 18-19 19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :



G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:CLASS10:Atom 11:CLASS12:CLASS13:CLASS
14:CLASS15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

10/518,043

=>

Uploading C:\Program Files\Stnexp\Queries\10518043.str



chain nodes :

7 9 11 12 13 14

ring nodes :

1 2 3 4 5 6 15 16 17 18 19 20

chain bonds :

2-13 9-11 9-12 13-14 14-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

exact/norm bonds :

2-13 9-11 9-12 13-14 14-19 15-16 15-20 16-17 17-18 18-19 19-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10/518,043



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 12:54:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11862 TO ITERATE

16.9% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

8 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 230714 TO 243766

PROJECTED ANSWERS: 535 TO 1361

L2 8 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 12:56:28 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 237346 TO ITERATE

100.0% PROCESSED 237346 ITERATIONS
SEARCH TIME: 00.00.02

681 ANSWERS

L3 681 SEA SSS FUL L1

=> => s l3

L4 19 L3

=> d l4 1-19 bib,ab,hitstr

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:384238 CAPLUS
 DN 146:380007
 TI Preparation of heterocyclic Met kinase inhibitors for use in treating cancer
 IN Borzilleri, Robert M.; Chen, Xiao-Tao; Williams, David K.; Tokarski, John S.; Kaltenbach, Robert F.
 PA Bristol-Myers Squibb Company, USA
 SO U.S. Pat. Appl. Publ., 54pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007078140	A1	20070405	US 2006-529875	20060928
	WO 2007041379	A1	20070412	WO 2006-US38216	20060929
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-722089P P 20050930
 US 2006-529875 A 20060928

OS MARPAT 146:380007

AB The present invention is directed to compds. having the formula I or II (wherein R1 is H, halo, halogenated alkyl, etc.; A is substituted pyrimidine, etc.; B is O, S, etc.; W and X are C or N; V is CO; Y is (un)substituted Ph, (un)substituted pyridine, etc.; n is 1-4; p is 0-2; R2 is H, (un)substituted alkyl, or (un)substituted cycloalkyl; R3 and R4 are H, halogen, (un)substituted alkyl, etc. or taken together form a carbocyclic or heterocyclic ring; R5 is (un)substituted alkyl, haloalkyl, cycloalkyl, etc.) including salts thereof, and methods for using them for the treatment of cancer. Example compound III was prepared by reacting 4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorobenzenamine (preparation given) and 4-chloro-N-(2,4-difluorophenyl)nicotinamide (preparation given). No biol. data is given in the patent.

IT 931105-72-5P, 4-[[4-[(2-Aminopyridin-4-yl)oxy]-3-fluorophenyl]amino]-2-(benzylamino)-N-(2,4-difluorophenyl)pyrimidine-5-carboxamide trihydrochloride


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic Met kinase inhibitors for use in treating cancer)

RN 931105-72-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]amino]-N-(2,4-difluorophenyl)-2-[(phenylmethyl)amino]-, hydrochloride (1:3) (CA INDEX NAME)


10/518,043



● 3 HCl


L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1331193 CAPLUS
 DN 146:134607
 TI Synthesis and evaluation of 2-([2-(4-hydroxyphenyl)-ethyl]amino)pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors
 AU Nagashima, Shinya; Yokota, Masaki; Nakai, Ei-ichi; Kuromitsu, Sadao; Ohga, Keiko; Takeuchi, Makoto; Tsukamoto, Shin-ichi; Ohta, Mitsuaki
 CS Institute for Drug Discovery Research, Astellas Pharm Inc., Yodogawa-ku, Osaka, 532-8514, Japan
 SO Bioorganic & Medicinal Chemistry (2007), 15(2), 1044-1055
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 146:134607
 AB The STAT6 (signal transducers and activators of transcription 6) protein is activated by interleukin (IL)-4 and IL-13, and plays an important role in T-helper cell 2 (Th2) differentiation. STAT6 might therefore be an excellent therapeutic target for various allergic conditions, including asthma and atopic diseases. We synthesized a series of 2-([2-(4-hydroxyphenyl)ethyl]amino)pyrimidine-5-carboxamide derivs. and evaluated their STAT6 inhibitory activities. Among these compds., 4-(benzylamino)-2-([2-(3-chloro-4-hydroxyphenyl)ethyl]amino)pyrimidine-5-carboxamide (2t, 1) showed potent STAT6 inhibition with an IC50 value of 21 nM, and also inhibited IL-4-induced Th2 differentiation of mouse spleen T cells with an IC50 value of 2.3 nM and without influencing T-helper cell 1 (Th1) differentiation induced by IL-12.
 IT 227450-22-8P 643087-50-7P 643087-53-0P
 643088-72-6P 643088-74-8P 643088-77-1P
 643088-78-2P 643088-79-3P 643089-05-8P
 643089-06-9P 643089-07-0P 643089-08-1P
 643089-31-0P 643089-32-1P 919486-35-4P
 919486-36-5P 919486-37-6P 919486-38-7P
 919486-39-8P 919486-40-1P 919486-41-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pyrimidinecarboxamide derivs. as STAT6 inhibitors)
 RN 227450-22-8 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-([2-(4-hydroxyphenyl)ethyl]amino)-4-[(3-methylphenyl)amino]- (CA INDEX NAME)

Common Auth.




RN 643087-50-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-bromo-4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643087-53-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclohexylamino)-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (CA INDEX NAME)




RN 643088-72-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643088-74-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643088-77-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-fluoro-4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643088-78-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643088-79-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxy-3-methylphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-05-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-methyl-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-06-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N,N-dimethyl-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-07-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-ethyl-2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-08-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-(1-methylethyl)-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-31-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-(phenylamino)- (CA INDEX NAME)




RN 643089-32-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 919486-35-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)




RN 919486-36-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-methoxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 919486-37-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[4-(hydroxyphenyl)methyl]methyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 919486-38-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(4-hydroxyphenyl)propyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 919486-39-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(2-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 919486-40-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 919486-41-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-N-methyl-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:941059 CAPLUS
 DN 145:336066
 TI Preparation of pyrrolo[2,3-d]pyrimidine derivatives or their salts as inhibitors for activation of signal transducer and activator of transcription 6 (STAT6)
 IN Nagashima, Shinya; Hondo, Takeshi; Nagata, Hiroshi; Ogiyama, Takashi; Hoshii, Hiroaki; Kontani, Toru; Oga, Keiko; Kuromitsu, Sadao
 PA Astellas Pharma Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 88pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006241089	A	20060914	JP 2005-59945	20050304
PRAI	JP 2005-59945		20050304		
OS	MARPAT 145:336066				

AB The title compds. [I; A = C(R₀), N; R₁ = H, (un)substituted lower alkyl, cyano, (un)substituted heterocyclyl, -L-R_{1a}; O, NR₀, S, SO₂, CO CO₂, O₂C, CONR₀, NROCO, NROCONR_{0a}, NR₀ CO₂, O-lower alkylene, NR₀-lower alkylene, S-lower alkylene, SO₂-lower alkylene, CO-lower alkylene, CO₂-lower alkylene, O₂C-lower alkylene, CONR₀-lower alkylene, NROCO-lower alkylene; R_{1a} = H, (un)substituted lower alkyl, cycloalkyl, lower alkylene-cycloalkyl, aryl, lower alkylene-aryl, etc.; R₂ = H, cyano, lower alkyl, halo-lower alkyl, lower alkylene-OR₀, halo, OR₀, O-haloalkyl, O-lower alkylene-NR_{0R0a}, O-lower alkylene-CO₂R₀, CONR_{0R0a}, etc.; R₃ = H, lower alkyl, halo, OR₀, NR_{0R0a}, lower alkylene-OR₀, lower alkylene-NR_{0R0a}, NR_{0COR0a}, aryl, O-aryl, etc.; R₄ = H, CO₂ R₀, COR_{0R0a}; R₅ = lower alkyl, aryl, lower alkylene-aryl, lower alkylene-heterocyclyl; wherein R₀, R_{0a} = H, lower alkyl] are prepared These compds. selectively inhibit the activation of STAT6, i.e. tyrosine phosphorylation of STAT6, exhibit higher STAT6 activation-inhibitory activity than immune cell activation-inhibitory activity, and are useful for the prevention and/or treatment of respiratory diseases (asthma or chronic obstructive lung disease) and allergic diseases (rhinitis or dermatitis). Thus, 4-[[7-(2,5-Difluorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzoic acid was treated with a solution of 1-methylpiperidin-4-amine in DMF, HOBT, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and stirred at room temperature for 24 h to give 4-[[7-(2,5-difluorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-N-(1-methylpiperidin-4-yl)benzamide (II). II in vitro inhibited the IL-4 stimulated production of luciferase in STAT6 reporter CI/FW4 cells by 99%.


IT 909562-71-6P, 4-[(2,6-Difluorobenzyl)amino]-N-methoxy-N-methyl-2-[[4-[(1-methylpiperidin-3-yl)oxy]phenyl]amino]pyrimidine-5-carboxamide
 909562-75-0P, N-Methoxy-N-methyl-2-[[4-(morpholin-4-yl)phenyl]amino]-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolo[2,3-d]pyrimidine derivs. as inhibitors for activation of signal transducer and activator of transcription 6 (STAT6) for treatment or prevention of STAT6-related diseases)

RN 909562-71-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[[(2,6-difluorophenyl)methyl]amino]-N-methoxy-N-methyl-2-[[4-[(1-methyl-3-piperidinyl)oxy]phenyl]amino]- (CA INDEX NAME)

10/518,043




RN 909562-75-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-methoxy-N-methyl-2-[[4-(4-morpholinyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-N-methyl-2-methoxy-N-methyl-5-pyrimidinecarboxamide (CA INDEX NAME)



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:681435 CAPLUS
 DN 145:137879
 TI Pyrimidine derivative kinase modulators and therapeutic use
 IN Chen, Jeff; Dalrymple, Lisa Esther; Epshteyn, Sergey; Forsyth, Timothy
 Patrick; Huynh, Tai Phat; Ibrahim, Mohamed Abdulkader; Leahy, James W.;
 Lewis, Gary Lee; Mann, Grace; Mann, Lary W.; Noguchi, Robin Tammie;
 Ridgway, Brian Hugh; Sangalang, Joan Cruz; Schnepp, Kevin Luke; Shi, Xian;
 Takeuchi, Craig Stacy; Williams, Matthew Alan; Nuss, John; Cheung, Atwood
 K.
 PA Exelixis, Inc., USA
 SO PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006074057	A2	20060713	WO 2005-US47402	20051228
	WO 2006074057	A3	20061026		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005322855	A1	20060713	AU 2005-322855	20051228
	CA 2590110	A1	20060713	CA 2005-2590110	20051228
PRAI	US 2004-640439P	P	20041230		
	US 2005-704863P	P	20050801		
	WO 2005-US47402	W	20051228		
OS	MARPAT 145:137879				
AB	The invention provides pyrimidine derivs. and methods for inhibition of kinases, more specifically IGF1R kinases. The invention also provides compds. and methods for inhibition of wildtype Abl. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Preparation of pyrimidine derivs. is included.				
IT	898278-52-9 898278-77-8 898279-00-0 898288-19-2				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrimidine derivative kinase modulators and therapeutic use)				
RN	898278-52-9 CAPLUS				
CN	4-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[2-(4-morpholinyl)ethyl]-5-nitro- (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898278-77-8 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-(1-methylethyl)-5-nitro- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898279-00-0 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-nitro-N-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898288-19-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-nitro-N-(phenylmethyl)- (CA INDEX NAME)

10/518,043



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


L4 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:318326 CAPLUS
 DN 144:370115
 TI Preparation of HIV-inhibiting 5-substituted pyrimidines
 IN Guillemont, Jerome Emile Georges; Heeres, Jan; Lewi, Paulus Joannes
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 49 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006035069	A1	20060406	WO 2005-EP54932	20050929
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005288866	A1	20060406	AU 2005-288866	20050929
	CA 2575472	A1	20060406	CA 2005-2575472	20050929
	EP 1797047	A1	20070620	EP 2005-789686	20050929
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	CN 101027288	A	20070829	CN 2005-80032553	20050929
	IN 2007DN01391	A	20070817	IN 2007-DN1391	20070221
PRAI	EP 2004-104805	A	20040930		
	WO 2005-EP54932	W	20050929		
OS	CASREACT 144:370115; MARPAT 144:370115				
AB	5-Substituted pyrimidines HIV replication inhibitors [I; A = CH ₂ CH ₂ , CH:CH, C.tplbond.C; R ₁ = hydrogen, aryl, formyl, C ₁ -6 alkylcarbonyl, C ₁ -6 alkyl, C ₁ -6 (alkyloxy)carbonyl; R ₂ = hydroxy, halo, C ₁ -6 alkyl, carboxyl, cyano, C(:O)R ₆ , nitro, (un)substituted amino, polyhalomethyl; X ₁ = NR ₁ , O, S, S(:O)p; R ₃ , R ₄ = H, C ₁ -6 alkyl, halogen; R ₅ = nitro, (un)substituted amino, aryl, halogen, CHO, COR ₆ , CO ₂ R ₇ , NHCHO, -NHC(:O)R ₆ , CH:NOR ₈ ; R ₆ = C ₁ -4 alkyl, (un)substituted amino, polyhalo C ₁ -4 alkyl; R ₇ = hydrogen, C ₁ -6 alkyl, arylalkyl; R ₈ = hydrogen, C ₁ -6 alkyl, aryl; p = 1,2], which demonstrate HIV reverse transcriptase inhibition, are prepared and pharmaceutical compns. containing them are presented.				
IT	882187-60-2P 882187-61-3P 882187-69-1P 882187-71-5P 882187-72-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of HIV-inhibiting 5-substituted pyrimidines)				
RN	882187-60-2 CAPLUS				
CN	5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-propyl- (CA INDEX NAME)				


Double bond geometry as shown.



RN 882187-61-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]- (CA INDEX NAME)

Double bond geometry as shown.



RN 882187-69-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[4-(2-cyanoethyl)-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]- (CA INDEX NAME)



RN 882187-71-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N,N-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 882187-72-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-[(4-cyanophenyl)amino]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:497492 CAPLUS
 DN 143:7727
 TI Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of
 PKC-theta for treating diseases associated with T cells activation, in
 particular immunol. disorders and type II diabetes
 IN Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, George;
 Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denice
 M.; Young, Erick Richard Roush
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim
 Pharma G.m.b.H. & Co. K.-G.
 SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 766,079.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005124640	A1	20050609	US 2004-933635	20040903
	US 2004242613	A1	20041202	US 2004-766079	20040127
PRAI	US 2003-443700P	P	20030130		
	US 2004-766079	A2	20040127		

OS MARPAT 143:7727

AB Title compds. I [wherein R1 = (un)substituted
 heteroaryl/aryl/cyclo/cycloalkyl/alkyl, naphthyl, quinolinyl, etc.; R2 =
 (un)substituted -NH-CH2-(CH2)n-CH2-NR4R5, -NH-(CH2)p-phenylene-(CH2)q-
 NR4R5, -NH(CH2)p-X-R4, etc.; X = piperidinyl; n = 3-8; p = 1-3; q = 0-3;
 R4, R5 = independently H, amidino, (un)substituted aryl/alkyl; R3 = halo,
 CN, NO2, aminocarbonyl, (un)substituted alkyl, alkyloxycarbonyl; their
 tautomers, pharmaceutically acceptable salts, solvates, or amino-protected
 derivs., with certain compds. excluded] were prepared as inhibitors of
 protein kinase C (PKC)-theta useful for treating immunol. disorders and
 type II diabetes. For example, II was prepared in 5 steps via amination of
 2,4-dichloro-5-fluoropyrimidine with amine III and 2-chlorobenzylamine.
 Selected I inhibited PKC-theta with IC50 values $\leq 0.3 \mu\text{M}$. Thus,
 I are useful for treating a disease or disorder associated with T cells
 activation.

IT 736046-89-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta
 inhibitors for treating diseases associated with T cells activation, in
 particular immunol. disorders and type II diabetes)

RN 736046-89-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[4-(aminomethyl)cyclohexyl)methyl]amino]-2-
 [[(2-chlorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Same
as
#9




IT 736054-62-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)

RN 736054-62-9 CAPLUS

CN Carbamic acid, [[4-[[[5-(aminocarbonyl)-2-[[[(2-chlorophenyl)methyl]amino]-4-pyrimidinyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:371230 CAPLUS
 DN 142:430289
 TI Preparation of pyrimidine compounds as mixed lymphocyte reaction (MLR) inhibitors
 IN Tsuruoka, Hiroyuki; Matsuda, Akihisa; Sugano, Yuichi; Tatsuta, Toru
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 350 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005037801	A1	20050428	WO 2004-JP15955	20041021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005145956	A	20050609	JP 2004-302344	20041018
PRAI JP 2003-360967	A	20031021		
OS MARPAT 142:430289				

AB Disclosed is a pyrimidine derivative with excellent MLR inhibitory effect or a pharmacol. acceptable salt thereof. Pyrimidine derivs. represented by the general formula (I) or pharmacol. acceptable salts thereof [R1 = lower alkyl; R2 = each (un)substituted aryl or heterocyclyl; A = NH, O; R3 = H, lower alkyl, heterocyclyl, aryl, heterocyclyl, -NHR6 (wherein R6 = lower alkyl, cycloalkyl-lower alkyl, aralkyl, each (un)substituted cycloalkyl, aryl, or heterocyclyl); R4 = H, lower alkyl, lower alkoxy, cycloalkyl-lower alkyl, aralkyl, each (un)substituted aryl or heterocyclyl; provided that R3 = R4 ≠ H; R5 = H, halo, lower alkyl, cycloalkyl, (un)substituted heterocyclyl, NR7R8, OR7 (wherein R7, R8 = H, cycloalkyl, (un)substituted aryl or lower alkyl)] are prepared. These compds. exhibit excellent MLR inhibitory effect and are useful as inhibitors of allograft rejection in bone marrow and organ transplant or for the prevention and/or treatment of inflammatory diseases, organ-specific or organ-nonspecific autoimmune diseases, allergic diseases, chronic rheumatism, multiple sclerosis, inflammatory bowel disease, diabetes, glomerulonephritis, primary biliary liver cirrhosis, chronic active hepatitis, pernicious anemia, chronic thyroiditis, atrophic gastritis, myasthenia gravis, psoriasis, Sjogren's syndrome, systemic lupus erythematosus, rhinitis, asthma, or atopic dermatitis. Thus, 0.1 mmol 4-hydrazino-2,6-bis(2-methoxyphenylamino)pyrimidine was dissolved in 1 mL ethanol, treated with 0.1 mmol 4-acetylpyridine, and stirred for 18 h to give 4-[N'-(1-(pyridin-4-yl)ethylidene)hydrazino]-2,6-bis(2-methoxyphenylamino)pyrimidine. N-methyl-4-[1-[[5-phenyl-2-phenylamino-6-[4-(pyridin-4-yl)pyrazol-1-yl]pyrimidin-4-yl]hydrazono]ethyl]benzenesulfonamide (II) inhibited MLR in human peripheral hemolymphocyte offered from two healthy people with IC50 of 1.0 ng/mL.


IT 850756-09-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/518,043

(preparation of pyrimidine compds. as mixed lymphocyte reaction (MLR) inhibitors)

RN 850756-09-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[[1-[4-(methylsulfonyl)phenyl]ethylidene]hydrazino]-5-phenyl-2-(phenylamino)-, [1-[4-(methylsulfonyl)phenyl]ethylidene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:99357 CAPLUS
 DN 142:198088
 TI Preparation of pyrimidinecarboxamides, pyrimidinylcarbamates and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases
 IN Nunes, Joseph J.; Zhu, Xiaotian; Amouzegh, Patricia; Ghiron, Chiara; Johnston, David N.; Power, Eoin Christopher
 PA Amgen Inc., USA
 SO PCT Int. Appl., 462 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009443	A1	20050203	WO 2004-US20243	20040624
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005209221	A1	20050922	US 2004-875896	20040623
	AU 2004258862	A1	20050203	AU 2004-258862	20040624
	CA 2529734	A1	20050203	CA 2004-2529734	20040624
	EP 1648464	A1	20060426	EP 2004-777011	20040624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-482375P	P	20030624		
	US 2004-875896	A	20040623		
	WO 2004-US20243	W	20040624		

OS MARPAT 142:198088

AB Pyrimidine and pyridine carboxamides I [wherein X = N or CH; Y = NH, O or S; R1 - R3 = certain (un)substituted monocyclic or bicyclic ring; or pharmaceutically acceptable salts thereof] as well as pyrimidinylcarbamates were prepared as inhibitors of T cell activation. For example, 2,4-dichloropyrimidine-5-carbonyl chloride, obtained by globally chlorination of uracil-5-carboxylic acid monohydrate with PCl₅ in POCl₃, underwent amidation with 2,6-dimethylaniline, followed by etherification with 3-chlorophenol and subsequent amination with 3-fluoro-4-(3-(4-methyl-1-piperazinyl)propoxy)aniline to give pyrimidinecarboxamide II. Representative compds. I exhibited inhibition with IC₅₀ values of <10 μM in the LCK-homogeneous time resolved fluorescent kinase assay. Therefore, I and pharmaceutical compns. thereof are useful in the treatment of many diseases such as inflammation.

IT 835639-24-2P, N-(2,6-Dimethylphenyl)-2,4-bis(phenylamino)-5-pyrimidinecarboxamide 835639-25-3P 835639-29-7P, N-(2,6-Dimethylphenyl)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-(phenylamino)-5-pyrimidinecarboxamide 835639-30-0P, N-(2,6-Dimethylphenyl)-2-[[3-fluoro-4-[[3-(1-piperidinyl)propyl]oxy]phenyl]amino]-4-(phenylamino)-5-pyrimidinecarboxamide 835639-31-1P, N-(2,6-Dimethylphenyl)-2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-(phenylamino)-5-pyrimidinecarboxamide 835639-32-2P, N-(2,6-Dimethylphenyl)-2-[[4-[4-(1-methylethyl)-1-


piperazinyl]phenyl]amino]-4-(phenylamino)-5-pyrimidinecarboxamide
 835639-33-3P, 2-[[4-[4-[2-(Dimethylamino)ethyl]-1-piperazinyl]phenyl]amino]-N-(2,6-dimethylphenyl)-4-(phenylamino)-5-pyrimidinecarboxamide 835639-34-4P, 2-[[4-[4-[3-(Dimethylamino)propyl]-1-piperazinyl]phenyl]amino]-N-(2,6-dimethylphenyl)-4-(phenylamino)-5-pyrimidinecarboxamide 835639-35-5P, 2-[[4-[[[2-(Dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-N-(2,6-dimethylphenyl)-4-(phenylamino)-5-pyrimidinecarboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of pyrimidinecarboxamides and pyrimidinylcarbamates as inhibitors of T cell activation for treatment of inflammatory diseases)

RN 835639-24-2 CAPLUS


CN 5-Pyrimidinecarboxamide, N-(2,6-dimethylphenyl)-2,4-bis(phenylamino)-(9CI) (CA INDEX NAME)

R' & R² are NOT aryl in the claims.




RN 835639-25-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2,6-dimethylphenyl)-2-[[3-fluoro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-(phenylamino)-(9CI) (CA INDEX NAME)




RN 835639-29-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2,6-dimethylphenyl)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-(phenylamino)-(9CI) (CA INDEX NAME)




RN 835639-30-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2,6-dimethylphenyl)-2-[[3-fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]amino]-4-(phenylamino)-(9CI) (CA INDEX NAME)




RN 835639-31-1 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2,6-dimethylphenyl)-2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-(phenylamino)- (9CI) (CA INDEX NAME)




RN 835639-32-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2,6-dimethylphenyl)-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-(phenylamino)- (9CI) (CA INDEX NAME)



RN 835639-33-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]phenyl]amino]-N-(2,6-dimethylphenyl)-4-(phenylamino)- (9CI) (CA INDEX NAME)



RN 835639-34-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[4-[3-(dimethylamino)propyl]-1-piperazinyl]phenyl]amino]-N-(2,6-dimethylphenyl)-4-(phenylamino)- (9CI) (CA INDEX NAME)

10/518,043



RN 835639-35-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-N-(2,6-dimethylphenyl)-4-(phenylamino)- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:648512 CAPLUS
 DN 141:190795
 TI Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of
 PKC-theta for treating diseases associated with T cells activation, in
 particular immunol. disorders and type II diabetes
 IN Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, Georg;
 Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denice
 M.; Young, Erick Richard Roush
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim
 Pharma GmbH & Co. KG
 SO PCT Int. Appl., 124 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067516	A1	20040812	WO 2004-US2240	20040127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	CA 2514612	A1	20040812	CA 2004-2514612	20040127
	EP 1590334	A1	20051102	EP 2004-705675	20040127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006515014	T	20060518	JP 2005-518568	20040127
PRAI	US 2003-443700P	P	20030130		
	WO 2004-US2240	W	20040127		


OS MARPAT 141:190795

AB Title compds. I [wherein R1 = (un)substituted
 heteroaryl/aryl/cyclo/cycloalkyl/alkyl, naphthyl, quinolinyl, etc.; R2 =
 (un)substituted -NH-CH2-(CH2)n-CH2-NR4R5, -NH-(CH2)p-phenylene-(CH2)q-
 NR4R5, -NH(CH2)p-X-R4, etc.; X = pyridinyl; n = 3-8; p = 1-3; q = 0-3; R4,
 R5 = independently H, amidino, (un)substituted aryl/alkyl; R3 = halo, CN,
 NO2, aminocarbonyl, (un)substituted alkyl, alkyloxycarbonyl; their
 tautomers, pharmaceutically acceptable salts, solvates, or amino-protected
 derivs., with certain compds. excluded] were prepared as inhibitors of
 protein kinase C (PKC)-theta useful for treating immunol. disorders and
 type II diabetes. For example, II was prepared in 5 steps via amination of
 2,4-dichloro-5-fluoropyrimidine with amine III and 2-chlorobenzylamine.
 Selected I inhibited PKC-theta with IC50 values ≤ 0.3 μM. Thus,
 I are useful for treating a disease or disorder associated with T cells
 activation.

IT 736046-89-2P, 4-[[[4-(Aminomethyl)cyclohexyl)methyl]amino]-2-[(2-
 chlorobenzyl)amino]pyrimidine-5-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta
 inhibitors for treating diseases associated with T cells activation, in
 particular immunol. disorders and type II diabetes)

RN 736046-89-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[4-(aminomethyl)cyclohexyl)methyl]amino]-2-
 [[(2-chlorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



* n is 0 or 2
in the claims.


IT 736054-62-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)

RN 736054-62-9 CAPLUS

CN Carbamic acid, [[4-[[[5-(aminocarbonyl)-2-[[2-(2-chlorophenyl)methyl]amino]-4-pyrimidinyl]amino]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:589247 CAPLUS
 DN 141:140463
 TI Preparation of heterocyclic compounds as selective phosphodiesterase V inhibitors
 IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
 PA Japan
 SO U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S. Ser. No. 258,545.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

Same as #14.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142930	A1	20040722	US 2003-699804	20031104
	JP 2002012587	A	20020115	JP 2000-277652	20000913
	JP 3637961	B2	20050413		
	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003229089	A1	20031211	US 2002-258545	20021025
	US 7220736	B2	20070522		
PRAI	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		
	JP 1999-261852	A	19990916		
OS	MARPAT 141:140463				
AB	<p>The title compds. (I) [X = CH, N; Y = NH, NR, S, O, CH:N, N:CH, N:N, CH:CHC(:R5)N, CH:C(R5), N:C(R7); R1 = each (un)substituted lower alkoxy, amino, heterocyclyl containing N atom(s), HO, or heterocyclyloxy containing N atom(s), cyano; R2 = lower alkylamino or lower alkoxy each optionally substituted by an (un)substituted aryl, lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), lower alkylamino group substituted by a (un)substituted heterocyclic ring, (un)substituted arylamino; R3 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkyl, lower alkoxy, lower cycloalkoxy, heterocyclyloxy containing N atom(s), or NH2; R4-R7 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkoxy, or NH2; R4, R5, R6 or R7 may combine with R3 to form a lactone ring Q or Q1; when X = N, Y = CH:N, or N:CH, R2 = an amino group monosubstituted by an (un)substituted arylmethyl, and R3 = (un)substituted lower alkyl, amino monosubstituted by an (un)substituted heterocyclyl-lower alkyl containing N atom(s) in the ring, heterocyclylamino containing N atom(s) in the ring, or (un)substituted lower cycloalkylamino, R1 = each (un)substituted lower alkoxy, amino, heterocyclyloxy containing N atom(s) in the ring, or cyano group] or pharmacol. acceptable salts thereof are prepared These compds. have excellent selective PDE V inhibitory activity and therefore, are useful as therapeutic or prophylactic drugs for treating various diseases due to functional disorders on cGMP-signaling, such as erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis. Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF and etherified with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine to</p>				

give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.


IT 372115-17-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as selective phosphodiesterase V inhibitors for treating various diseases due to functional disorders on cGMP-signaling)

RN 372115-17-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[(phenylmethyl)amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:20665 CAPLUS
 DN 140:94057
 TI Preparation of 2,4-diaminopyrimidine-5-carboxamide derivatives as
 inhibitors of signal transducer and activator of transcription (STAT6)
 IN Nagashima, Shinya; Nagata, Hiroshi; Iwata, Masahiro; Yokota, Masaki;
 Moritomo, Hiroyuki; Nakai, Eiichi; Kuromitsu, Sadao; Ohga, Keiko;
 Takeuchi, Makoto
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

*Appd.
PCT*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002964	A1	20040108	WO 2003-JP8129	20030626
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490888	A1	20040108	CA 2003-2490888	20030626
	AU 2003244098	A1	20040119	AU 2003-244098	20030626
	EP 1518855	A1	20050330	EP 2003-761820	20030626
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1665789	A	20050907	CN 2003-815071	20030626
	MX 2004PA12855	A	20050419	MX 2004-PA12855	20041216
	US 2005272753	A1	20051208	US 2004-518043	20041216
	IN 2004DN04092	A	20070105	IN 2004-DN4092	20041222
PRAI	JP 2002-190959	A	20020628		
	WO 2003-JP8129	W	20030626		

OS MARPAT 140:94057

AB Disclosed are STAT6 activation inhibitors containing 2-(arylamino or aryylethylamino)-4-aminopyrimidine-5-carboxamide derivs. [I; A1 = CR5, N; R5 = H, lower alkyl, lower alkoxy, halo; A2 = CR6, N; R6 = H, halo; R3 = R, lower haloalkyl, halo, OR, lower alkylthio, lower alkyl-carbonyl, lower alkoxy-carbonyl, lower hydroxyalkyl, heterocyclyl, heterocyclyloxy, NR-heterocyclyl, heterocyclyl-lower alkyl, heterocyclyl-lower alkoxy, heterocyclyl-lower alkylthio, heterocyclyl-lower alkylsulfinyl, heterocyclyl-lower alkylsulfonyl, etc.; R = H, lower alkyl; n = 0, 2; when n = 2, R4 = R, lower haloalkyl, OR, NRCHO, NR-CO-lower alkyl, NR-SO2-lower alkyl, etc.; when n = 0, R4 = H, lower haloalkyl, HO, NHCHO, CONR2, lower halohydroxyalkyl, amino-lower alkyl, ureido-lower alkyl, carboxy-lower alkyl, lower alkoxy-carbonyl-lower alkyl, cyano-lower alkyl, bis(hydroxy-lower alkyl)methyl, etc.; R1, R2 = H, (un)substituted lower alkyl or alkoxy; B = H, lower alkenyl, lower alkynyl, halo-lower alkyl, cyano, lower alkylthio, each (un)substituted aryl, cycloalkyl, or heterocyclyl; Y = a single bond, (un)substituted lower alkylene] or pharmaceutically acceptable salts thereof and carriers. The said STAT6 activation inhibitors are differentiation inhibitors for Th2 cell, preventives and/or therapeutics for respiratory diseases, in particular asthma and chronic obstructive pulmonary diseases. Thus, 765 mg 2-(3-chloro-4-hydroxyphenyl)ethylamine hydrochloride and 1.07 mL


diisopropylethylamine were added to a solution of 4-benzylamino-2-methylsulfonylpyrimidine-5-carboxamide in 8 mL N-methylpyrrolidone and stirred at 110° for 1 h to give, after workup and silica gel chromatog., 4-benzylamino-2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]pyrimidine-5-carboxamide (II). II and 4-benzylamino-2-[[4-(morpholin-4-yl)phenyl]amino]pyrimidine-5-carboxamide inhibited the STAT6 activation by 89 and 100%, resp., at 0.1 µM, in a STAT6-dependent reporter assay using STAT6 reporter CI/FW cells.

IT 643082-20-6P 643083-12-9P 643083-25-4P
643084-23-5P 643084-79-1P 643084-82-6P
643084-88-2P 643085-20-5P 643086-88-8P
643087-50-7P 643087-52-9P 643087-53-0P
643087-55-2P 643087-57-4P 643087-58-5P
643087-61-0P 643087-62-1P 643087-63-2P
643087-64-3P 643087-65-4P 643087-67-6P
643087-69-8P 643087-70-1P 643087-71-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal transducer and activator of transcription (STAT6), Th2 cell differentiation inhibitors, and preventives and/therapeutics for respiratory diseases)


RN 643082-20-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-piperazinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-12-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2-aminophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-25-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-piperidinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643084-23-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643084-79-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[[methyl(trifluoroacetyl)amino]methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643084-82-6 CAPLUS


CN Carbamic acid, [2-[1-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-4-piperidiny]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 643084-88-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-[(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)oxy]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643085-20-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-piperidinyloxy)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-88-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-(1-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643087-50-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-bromo-4-hydroxyphenyl)ethyl]amino]-4-[[3-methylphenyl]amino]- (CA INDEX NAME)




RN 643087-52-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-


10/518,043

[(3-ethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-53-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclohexylamino)-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (CA INDEX NAME)




RN 643087-55-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-57-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(acetylamino)methyl]phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-58-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[[(aminocarbonyl)amino]methyl]phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-61-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(methylamino)methyl]phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 643087-62-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 643087-63-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[(dimethylamino)methyl]phenyl]amino]-4-[(3-methylphenyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643087-64-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(2-hydroxyethyl)phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-65-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-methoxyphenyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-67-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclohexylamino)-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643087-69-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(1-methylethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643087-70-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclopropylamino)-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643087-71-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(phenylamino)-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



IT 643082-16-0P 643082-17-1P 643082-18-2P
 643082-19-3P 643082-21-7P 643082-22-8P
 643082-23-9P 643082-24-0P 643082-25-1P
 643082-26-2P 643082-27-3P 643082-28-4P
 643082-29-5P 643082-30-8P 643082-31-9P
 643082-32-0P 643082-33-1P 643082-34-2P
 643082-35-3P 643082-36-4P 643082-37-5P

643082-38-6P 643082-39-7P 643082-40-0P
643082-41-1P 643082-42-2P 643082-43-3P
643082-44-4P 643082-45-5P 643082-46-6P
643082-47-7P 643082-48-8P 643082-49-9P
643082-50-2P 643082-51-3P 643082-52-4P
643082-53-5P 643082-54-6P 643082-55-7P
643082-56-8P 643082-57-9P 643082-58-0P
643082-59-1P 643082-60-4P 643082-61-5P
643082-62-6P 643082-63-7P 643082-64-8P
643082-65-9P 643082-66-0P 643082-67-1P
643082-68-2P 643082-69-3P 643082-70-6P
643082-71-7P 643082-72-8P 643082-73-9P
643082-74-0P 643082-75-1P 643082-76-2P
643082-77-3P 643082-78-4P 643082-79-5P
643082-80-8P 643082-81-9P 643082-82-0P
643082-83-1P 643082-84-2P 643082-85-3P
643082-86-4P 643082-87-5P 643082-88-6P
643082-89-7P 643082-90-0P 643082-91-1P
643082-92-2P 643082-93-3P 643082-94-4P
643082-95-5P 643082-96-6P 643082-97-7P
643082-98-8P 643082-99-9P 643083-00-5P
643083-01-6P 643083-02-7P 643083-03-8P
643083-05-0P 643083-07-2P 643083-08-3P
643083-09-4P 643083-10-7P 643083-13-0P
643083-14-1P 643083-15-2P 643083-18-5P
643083-20-9P 643083-22-1P 643083-23-2P
643083-27-6P 643083-28-7P 643083-30-1P
643083-31-2P 643083-32-3P 643083-34-5P
643083-36-7P 643083-38-9P 643083-40-3P
643083-42-5P 643083-44-7P 643083-46-9P
643083-48-1P 643083-49-2P 643083-51-6P
643083-53-8P 643083-54-9P 643083-56-1P
643083-58-3P 643083-60-7P 643083-62-9P
643083-64-1P 643083-65-2P 643083-67-4P
643083-69-6P 643083-71-0P 643083-73-2P
643083-76-5P 643083-81-2P 643083-85-6P
643083-88-9P 643083-91-4P 643083-94-7P
643083-97-0P 643084-00-8P 643084-03-1P
643084-05-3P 643084-07-5P 643084-08-6P
643084-09-7P 643084-11-1P 643084-13-3P
643084-15-5P 643084-17-7P 643084-19-9P
643084-20-2P 643084-22-4P 643084-25-7P
643084-27-9P 643084-29-1P 643084-31-5P
643084-33-7P 643084-35-9P 643084-37-1P
643084-39-3P 643084-41-7P 643084-43-9P
643084-45-1P 643084-47-3P 643084-49-5P
643084-51-9P 643084-53-1P 643084-55-3P
643084-57-5P 643084-59-7P 643084-61-1P
643084-63-3P 643084-65-5P 643084-67-7P
643084-69-9P 643084-71-3P 643084-73-5P
643084-75-7P 643084-77-9P 643084-80-4P
643084-84-8P 643084-86-0P 643084-90-6P
643084-93-9P 643084-94-0P 643084-96-2P
643084-98-4P 643085-00-1P 643085-02-3P
643085-04-5P 643085-06-7P 643085-08-9P
643085-10-3P 643085-12-5P 643085-13-6P
643085-15-8P 643085-16-9P 643085-22-7P
643085-26-1P 643085-28-3P 643085-32-9P
643085-34-1P 643085-38-5P 643085-42-1P
643085-46-5P 643085-50-1P 643085-54-5P


643085-57-8P 643085-61-4P 643085-63-6P
 643085-64-7P 643085-67-0P 643085-69-2P
 643085-72-7P 643085-74-9P 643085-77-2P
 643085-79-4P 643085-82-9P 643085-85-2P
 643085-87-4P 643085-89-6P 643085-92-1P
 643085-95-4P 643085-98-7P 643086-01-5P
 643086-03-7P 643086-04-8P 643086-07-1P
 643086-10-6P 643086-13-9P 643086-16-2P
 643086-19-5P 643086-22-0P 643086-25-3P
 643086-27-5P 643086-29-7P 643086-30-0P
 643086-32-2P 643086-34-4P 643086-36-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal
 transducer and activator of transcription (STAT6), Th2 cell
 differentiation inhibitors, and preventives and/therapeutics for
 respiratory diseases)


RN 643082-16-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-2-hydroxyphenyl)ethyl]amino]-4-
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-17-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-
 N-methyl-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-18-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-
 [(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-19-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(1-oxido-1-piperidiny)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-21-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-methyl-1-piperazinyl)oxy]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-22-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2-fluoro-6-hydroxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-23-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(acetamido)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-24-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 643082-25-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[(methylsulfonyl)amino]methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643082-26-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643082-27-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[(methylamino)methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643082-28-4 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[4-(2-aminoethyl)-1-piperidinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, trihydrochloride (9CI)
 (CA INDEX NAME)




● 3 HCl

RN 643082-29-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(β-D-glucopyranosyloxy)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643082-30-8 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-31-9 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-32-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[2-(2,5-difluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-33-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-34-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(3-chlorophenyl)methyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-35-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2-furanylmethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-36-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[(2-thienylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-37-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-38-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-39-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-40-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(chlorophenyl)methyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-41-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-42-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(methoxyphenyl)methyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-43-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-44-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-methoxyphenyl]methyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-45-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[4-chlorophenyl]methyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-46-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-47-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[4-methoxyphenyl]methyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-48-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2-methylphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-49-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2-chlorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-50-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2-methoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-51-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2,4-difluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-52-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-53-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3,5-difluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-54-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[5-chloro-2-fluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-55-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-hydroxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-56-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-methoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-57-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2,5-dimethoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-58-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-fluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-59-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[4-(4-morpholinyl)phenyl]amino]-4-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-60-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2,3-dimethoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-61-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[(pyrazinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643082-62-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-(hydroxymethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-63-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2,3-difluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-64-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(4-fluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-65-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(4-fluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-66-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(2-ethoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-67-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(2,6-dimethylphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-68-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(2-fluoro-5-methylphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-69-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-[(diethylamino)methyl]phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-70-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-[(3-hydroxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-71-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-[(3,5-dimethoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-72-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-[(3-chloro-2-methylphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-73-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-chloro-6-fluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-74-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-chloro-2,6-difluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-75-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-fluoro-6-methoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-76-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2,6-dichlorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-77-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-fluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-78-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2,6-difluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-79-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2,5-difluorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-80-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-81-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(hydroxymethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-82-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(methoxy-6-methylphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-83-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(2-hydroxyethoxy)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-84-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(5-chloro-2-hydroxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-85-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-fluoro-5-(hydroxymethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643082-86-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[[2-[(2-hydroxyethyl)amino]phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 643082-87-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-[(2-hydroxyethyl)methylamino]phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-88-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-[(diethylamino)methyl]phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-89-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2,6-dimethoxyphenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-90-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-(2-hydroxyethoxy)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-91-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[[[2-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-92-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-93-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[5-fluoro-2-(trifluoromethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-94-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-95-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(3-hydroxypropyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-96-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-(3-hydroxypropyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-97-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(2-hydroxyethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643082-98-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-(2-hydroxyethyl)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643082-99-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[[2-(methylthio)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643083-00-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2,6-dihydroxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-01-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(methylsulfonyl)phenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643083-02-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[[3-[(2-hydroxyethyl)methylamino]phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643083-03-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-(2-fluoro-5-methoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-05-0 CAPLUS

CN Benzoic acid, 3-[[[5-(aminocarbonyl)-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643083-07-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-[(2-hydroxyethyl)amino]phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-08-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[5-fluoro-2-methoxyphenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-09-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[[2,3,5-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-10-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[[2-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-13-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3-chlorophenyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-14-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[(2-thienylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-15-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[5-(2-thienyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-18-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[4-(2-chloro-5-thienyl)methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-20-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[(2-thiazolylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-22-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-hydroxy-1-piperidinyl)methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-23-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(4-thiomorpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-27-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-28-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-30-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-piperidinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-31-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(2-(1-piperidinyl)ethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-32-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-34-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-piperidinylcarbonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-36-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-piperidinylsulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-38-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[methyl(1-methyl-4-piperidinyl)amino]methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-40-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-[3-(1-methyl-4-piperidinyl)propyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-42-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-[4-(1-piperidinyl)butyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-44-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-46-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(2-oxo-1-piperidinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-48-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(1-methyl-4-piperidiny]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643083-49-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643083-51-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 643083-53-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[(2R,6R)-2,6-dimethyl-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 643083-54-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylcarbonyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-56-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-[(1-piperidinylcarbonyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-58-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[methyl(1-piperidinylcarbonyl)amino]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-60-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-62-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-64-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-formyl-1-piperazinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-65-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-67-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(2-methoxyethyl)-1-piperazinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-69-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(tetrahydro-1,4-oxazepin-4(5H)-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-71-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(4-piperidinyloxy)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643083-73-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-76-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(2R,5S)-2,5-dimethyl-1-piperazinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 643083-81-2 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643083-85-6 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-[(2R,5S)-2,4,5-trimethyl-1-piperazinyl]phenyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 643083-88-9 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]- (9CI) (CA INDEX NAME)

10/518,043




RN 643083-91-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-pyrrolidinyl)phenyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 643083-94-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(3-hydroxy-1-pyrrolidinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643083-97-0 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(acetylamino)-1-pyrrolidinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 643084-00-8 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 643084-03-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-[(phenylmethyl)amino]]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 643084-05-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[2-(3-cyano-1-pyrrolidinyl)phenyl]amino]-4-[(phenylmethyl)amino]]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 643084-07-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-(dimethylamino)-1-piperidinyl)phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 643084-08-6 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-benzoyl-1-piperazinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643084-09-7 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-phenoxy-1-piperidinyl)phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643084-11-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[4-[2-(dimethylamino)ethyl]-1-piperazinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643084-13-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-fluoro-1-piperidiny)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643084-15-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(3,3-difluoro-1-piperidiny)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643084-17-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-[[4-(2-pyrimidinyl)-1-piperazinyl]phenyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 643084-19-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(3,4-dihydro-2-methylspiro[isoquinoline-1(2H),4'-piperidin]-1'-yl)phenyl]amino]-4-[(phenylmethyl)amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 643084-20-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[4-[(dimethylamino)acetyl]-1-piperazinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 643084-22-4 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643084-25-7 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[[4-[2-(4-morpholinyl)ethyl]-1-piperidinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 643084-27-9 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[[4-[[2-(dimethylamino)ethyl]amino]carbonyl]-1-piperidinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 643084-29-1 CAPLUS

CN Carbamic acid, [[4-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-2-morpholinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 643084-31-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[2-(aminomethyl)-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 643084-33-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[(dimethylamino)methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 643084-35-9 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[(acetylamino)methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 643084-37-1 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[[[(dimethylamino)acetyl]amino]methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 643084-39-3 CAPLUS
 CN 1-Piperazineacetic acid, 4-[4-[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 643084-41-7 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[[4-(dimethylamino)-1-oxobutyl]-1-piperazinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, trihydrochloride (9CI)
 (CA INDEX NAME)




● 3 HCl

RN 643084-43-9 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(5-oxo-2-morpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643084-45-1 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(4-methyl-5-oxo-2-morpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 643084-47-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-methyl-2-morpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 643084-49-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(3R)-5-oxo-3-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643084-51-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(3R)-4-methyl-5-oxo-3-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 643084-53-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 643084-55-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643084-57-5 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-γ-oxo- (9CI) (CA INDEX NAME)




RN 643084-59-7 CAPLUS
 CN 1-Piperazinebutanoic acid, 4-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-γ-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 643084-61-1 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(3R)-3-morpholinylphenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 643084-63-3 CAPLUS
 CN 4-Morpholinecarboxylic acid, 3-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643084-65-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(3R)-4-methyl-3-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 643084-67-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(3S)-4-methyl-5-oxo-3-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 643084-69-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(3S)-3-morpholinylphenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 643084-71-3 CAPLUS
 CN 4-Morpholinecarboxylic acid, 3-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643084-73-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(3S)-4-methyl-3-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 643084-75-7 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[(phenylmethoxy)methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride


(9CI) (CA INDEX NAME)



● HCl

RN 643084-77-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[2-(hydroxymethyl)-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 643084-80-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[methyl(methylsulfonyl)amino]methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 643084-84-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[4-(3-aminopropyl)-1-piperazinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, trihydrochloride (9CI)
(CA INDEX NAME)



● 3 HCl


RN 643084-86-0 CAPLUS

CN Carbamic acid, [3-[4-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 643084-90-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2,5-difluorophenyl)methyl]amino]-2-[[4-[(1-methyl-3-piperidinyl)oxy]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643084-93-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-methyl-5-oxo-2-morpholinyl)phenyl]amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643084-94-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[5-(aminocarbonyl)-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643084-96-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[5-(aminocarbonyl)-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 643084-98-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(tetrahydro-1,4-oxazepin-4(5H)-yl)phenyl]amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 643085-00-1 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-[(1-methyl-3-piperidinyl)oxy]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 643085-02-3 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 643085-04-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(3R)-3-morpholinylphenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 643085-06-7 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643085-08-9 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 643085-10-3 CAPLUS

CN 2-Morpholinecarboxylic acid, 4-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643085-12-5 CAPLUS

CN 2-Morpholinecarboxylic acid, 4-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 643085-13-6 CAPLUS


CN 3-Morpholinecarboxylic acid, 4-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643085-15-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[4-(4-amino-4-oxobutyl)-1-piperazinyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643085-16-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[[4-(2-amino-2-oxoethyl)-1-piperazinyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643085-22-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 643085-26-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643085-28-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(3-piperidinyloxy)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643085-32-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 643085-34-1 CAPLUS

CN 1-Piperidineacetic acid, 3-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643085-38-5 CAPLUS

CN 1-Piperidineacetic acid, 3-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenoxy)- (9CI) (CA INDEX NAME)



RN 643085-42-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 643085-46-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643085-50-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[4-[[3-[(aminocarbonyl)amino]propyl]-1-piperazinyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI)
(CA INDEX NAME)




RN 643085-54-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI)
(CA INDEX NAME)



RN 643085-57-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI)
(CA INDEX NAME)



● 2 HCl

RN 643085-61-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643085-63-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 643085-64-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(1-piperazinylsulfonyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643085-67-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(1-piperidinyl)propyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643085-69-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(4-methyl-1-piperazinyl)-3-oxo-1-propenyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643085-72-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[3-hydroxy-1-[(4-methyl-1-piperazinyl)methyl]propyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, hydrochloride (10:29) (9CI) (CA INDEX NAME)



●29/10 HCl

RN 643085-74-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(4-methyl-1-piperazinyl)-1-(1-piperidinylmethyl)propyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, hydrochloride (10:37) (9CI) (CA INDEX NAME)



●37/10 HCl


RN 643085-77-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 643085-79-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[4-(1-piperazinylcarbonyl)-1-piperazinyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 643085-82-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 643085-85-2 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 643085-87-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(3-azetidinyloxy)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643085-89-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[(1-methyl-3-azetidinyloxy)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643085-92-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[1,4'-bipiperidin]-1'-ylphenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 643085-95-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(hydroxymethyl)[1,4'-bipiperidin]-1'-yl]phenyl]amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643085-98-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[[5-(aminocarbonyl)-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]benzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 643086-01-5 CAPLUS

10/518,043


CN 5-Pyrimidinecarboxamide, 2-[[4-(1-piperazinylcarbonyl)phenyl]amino]-4-
[[[(2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX
NAME)



● 2 HCl


RN 643086-03-7 CAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[[5-(aminocarbonyl)-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]hexahydro-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 643086-04-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(hexahydro-7-oxo-1H-1,4-diazepin-1-yl)phenyl]amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 643086-07-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(β -D-glucopyranosyloxy)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643086-10-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(β -D-glucopyranosylphenyl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643086-13-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(1-pyrrolidinylsulfonyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-16-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-19-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-22-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-25-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643086-27-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)-3-(trifluoromethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643086-29-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(4-morpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643086-30-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643086-32-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643086-34-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2,6-difluorophenyl)methyl]amino]-2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643086-36-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3,5-difluoro-4-(4-morpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



IT 643086-38-8P 643086-40-2P 643086-42-4P
 643086-44-6P 643086-46-8P 643086-48-0P
 643086-50-4P 643086-53-7P 643086-55-9P
 643086-57-1P 643086-59-3P 643086-61-7P
 643086-63-9P 643088-28-2P 643088-29-3P
 643088-30-6P 643088-31-7P 643088-32-8P
 643088-33-9P 643088-34-0P 643088-35-1P
 643088-36-2P 643088-37-3P 643088-38-4P
 643088-39-5P 643088-40-8P 643088-41-9P
 643088-42-0P 643088-43-1P 643088-44-2P
 643088-45-3P 643088-46-4P 643088-47-5P
 643088-48-6P 643088-49-7P 643088-50-0P
 643088-51-1P 643088-52-2P 643088-53-3P
 643088-54-4P 643088-55-5P 643088-56-6P
 643088-57-7P 643088-58-8P 643088-59-9P
 643088-60-2P 643088-61-3P 643088-62-4P
 643088-63-5P 643088-64-6P 643088-65-7P
 643088-66-8P 643088-67-9P 643088-68-0P
 643088-69-1P 643088-70-4P 643088-71-5P
 643088-72-6P 643088-73-7P 643088-74-8P
 643088-75-9P 643088-76-0P 643088-77-1P
 643088-78-2P 643088-79-3P 643088-80-6P
 643088-81-7P 643088-82-8P 643088-83-9P
 643088-84-0P 643088-85-1P 643088-86-2P
 643088-87-3P 643088-88-4P 643088-89-5P
 643088-90-8P 643088-91-9P 643088-92-0P
 643088-93-1P 643088-94-2P 643088-95-3P
 643088-96-4P 643088-97-5P 643088-98-6P
 643088-99-7P 643089-00-3P 643089-01-4P
 643089-02-5P 643089-03-6P 643089-04-7P
 643089-05-8P 643089-06-9P 643089-07-0P
 643089-08-1P 643089-09-2P 643089-10-5P
 643089-11-6P 643089-12-7P 643089-13-8P
 643089-14-9P 643089-15-0P 643089-16-1P
 643089-17-2P 643089-18-3P 643089-19-4P
 643089-20-7P 643089-21-8P 643089-22-9P


643089-23-0P 643089-24-1P 643089-25-2P
 643089-26-3P 643089-27-4P 643089-28-5P
 643089-29-6P 643089-30-9P 643089-31-0P
 643089-32-1P 643089-33-2P 643089-34-3P
 643089-35-4P 643089-36-5P 643089-37-6P
 643089-38-7P 643089-39-8P 643089-40-1P
 643089-41-2P 643089-42-3P 643089-43-4P
 643089-44-5P 643089-45-6P 643089-46-7P
 643089-47-8P 643089-48-9P 643089-49-0P
 643089-50-3P 643089-51-4P 643089-52-5P
 643089-53-6P 643089-54-7P 643089-55-8P
 643089-56-9P 643089-57-0P 643089-58-1P
 643089-59-2P 643089-60-5P 643089-61-6P
 643089-62-7P 643089-63-8P 643089-64-9P
 643089-65-0P 643089-66-1P 643089-67-2P
 643089-68-3P 643089-69-4P 643089-70-7P
 643089-71-8P 643089-72-9P 643089-73-0P
 643089-74-1P 643089-75-2P 643089-76-3P
 643089-77-4P 643089-78-5P 643089-79-6P
 643089-80-9P 643089-81-0P 643089-82-1P
 643089-83-2P 643089-84-3P 643089-85-4P
 643089-86-5P 643089-87-6P 643089-88-7P
 643089-89-8P 643089-90-1P 643089-91-2P
 643089-92-3P 643089-93-4P 643089-94-5P
 643089-95-6P 643089-96-7P 643089-97-8P
 643089-98-9P 643089-99-0P 643090-00-0P
 643090-01-1P 643090-02-2P 643090-03-3P
 643090-04-4P 643090-05-5P 643090-06-6P
 643090-07-7P 643090-08-8P 643090-09-9P
 643090-10-2P 643090-11-3P 643090-12-4P
 643090-13-5P 643090-14-6P 643090-15-7P
 643090-16-8P 643090-17-9P 643090-18-0P
 643090-19-1P 643090-20-4P 643090-21-5P
 643090-22-6P 643090-23-7P 643090-24-8P
 643090-25-9P 643090-26-0P 643090-27-1P
 643090-28-2P 643090-29-3P 643090-30-6P
 643090-31-7P 643090-32-8P 643090-33-9P
 643090-34-0P 643090-35-1P 643090-36-2P
 643090-37-3P 643090-38-4P 643090-39-5P
 643090-40-8P 643090-41-9P 643090-42-0P
 643090-43-1P 643090-44-2P 643090-45-3P
 643090-46-4P 643090-47-5P 643090-48-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal
 transducer and activator of transcription (STAT6), Th2 cell
 differentiation inhibitors, and preventives and/therapeutics for
 respiratory diseases)


RN 643086-38-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-4-
 [[(2-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-40-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2,5-difluorophenyl)methyl]amino]-2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643086-42-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643086-44-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-[2-(4-morpholinyl)ethyl]amino]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 643086-46-8 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[3-[methyl[2-(4-morpholinyl)ethyl]amino]phenyl
 amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 643086-48-0 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643086-50-4 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[3-(hydroxymethyl)-4-(4-morpholinyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643086-53-7 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[[3-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643086-55-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-[(diethylamino)methyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-57-1 CAPLUS

CN Benzoic acid, 5-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]-2-(2,6-dimethyl-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 643086-59-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(4-morpholinyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643086-61-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 643086-63-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643088-28-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[4-methylcyclohexyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-29-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclobutylamino)-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-30-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclopentylamino)-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-31-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(bicyclo[2.2.1]hept-2-ylamino)-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 643088-32-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[(4-methylbicyclo[2.2.1]hept-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 643088-33-9 CAPLUS

10/518,043

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[1S)-2-hydroxy-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643088-34-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[1R)-1-cyclohexylethyl]amino]-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643088-35-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(cyclohexylamino)-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 643088-36-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(cyclooctylamino)-2-[[2-(3,5-dichloro-4-

hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-37-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-(tricyclo[3.3.1.1.3,7]dec-2-ylamino)- (9CI) (CA INDEX NAME)




RN 643088-38-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(2-chlorophenyl)methyl]amino]-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-39-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(2-bromophenyl)methyl]amino]-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-40-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[2-(2,6-difluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-41-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[2-(3-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-42-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(3-chlorophenyl)methyl]amino]-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-43-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[2-(2-furanylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-44-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[2-(2-thienylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-45-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[2-(tetrahydro-2-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-46-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[2-(2,2-dimethylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-47-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-methylbutyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-48-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[1H-indol-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 643088-49-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-(1H-indazol-5-ylamino)- (9CI) (CA INDEX NAME)




RN 643088-50-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1,3-benzodioxol-5-ylamino)-2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-51-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]- (9CI) (CA INDEX NAME)




RN 643088-52-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[(5,6,7,8-tetrahydro-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-53-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-hydroxyphenyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-54-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[4-methoxyphenyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-55-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-56-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[[2-methoxyphenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-57-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[(2-methylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-58-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[(1-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-59-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[5-methyl-2-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-60-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-(3-quinolinylamino)- (9CI) (CA INDEX NAME)




RN 643088-61-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(2-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-62-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-(1-methylethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-63-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-(hydroxymethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-64-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-65-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-66-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(3,5-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-67-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(3,5-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-68-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-acetylphenyl)amino]-2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-69-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(4-fluoro-3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-70-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(2,4-difluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-71-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[[[(3-methylphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643088-72-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-
[(3-methylphenyl)amino]- (CA INDEX NAME)

RN 643088-73-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-[[4-(acetylamino)-3-
chlorophenyl]ethyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX
NAME)


RN 643088-74-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-hydroxyphenyl)ethyl]amino]-4-[(3-
methylphenyl)amino]- (CA INDEX NAME)




RN 643088-77-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-fluoro-4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643088-78-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643088-79-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxy-3-methylphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643088-80-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-81-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-82-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-(1-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-83-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-[(3-cyanophenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-84-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-((1,3-benzodioxol-5-ylamino)-2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643088-85-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-(cyclohexylamino)- (9CI) (CA INDEX NAME)



RN 643088-86-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 643088-87-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-


10/518,043

methylphenyl) amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 643088-88-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-(2-methoxyethyl)-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-89-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 643088-90-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[3-(dimethylamino)propyl]-2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-91-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-(3-methoxypropyl)-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 643088-92-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 643088-93-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 643088-94-2 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-methoxy-4-
 [(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643088-95-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 643088-96-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



10/518,043


RN 643088-97-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 643088-98-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




RN 643088-99-7 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 643089-00-3 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-

10/518,043


methylphenyl)amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 643089-01-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 643089-02-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 643089-03-6 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)




RN 643089-04-7 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 643089-05-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-methyl-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-06-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N,N-dimethyl-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-07-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-ethyl-2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-08-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-N-(1-methylethyl)-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 643089-09-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 643089-10-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-hydroxyethyl)-2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-11-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-N-methyl-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 643089-12-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-[[3-(1-hydroxyethyl)phenyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 643089-13-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-

10/518,043


4-[(3-methylphenyl)amino]-N-[2-(4-morpholinyl)ethyl]-, dihydrochloride
(9CI) (CA INDEX NAME)



● 2 HCl

RN 643089-14-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-N-(2-hydroxyethyl)-4-[[3-(1-hydroxyethyl)phenyl]amino]-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl


RN 643089-15-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2,6-difluorophenyl)methyl]amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-16-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[[2-(2-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-17-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2,2-dimethylpropyl)amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-18-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylbutyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-19-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclopentylamino)-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-20-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-21-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2-chlorophenyl)methyl]amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-22-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[[2-(1H-indol-3-yl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-23-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[[[(3-methylphenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-24-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(ethylthio)ethyl]amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-25-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(3,5-difluorophenyl)methyl]amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-26-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(2,3-dichlorophenyl)methyl]amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-27-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(2-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-28-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-29-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-30-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3,5-dimethylphenyl)amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-31-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-(phenylamino)- (CA INDEX NAME)




RN 643089-32-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 643089-33-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643089-34-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(cyclohexylmethyl)amino]-2-[[2-(4-hydroxyphenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-35-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2-methylpropyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-36-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(1,1-dimethylethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 643089-37-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 643089-38-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(cyclopentylamino)-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-39-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(cyclohexylamino)-2-[[4-(4-

morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-40-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cycloheptylamino)-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-41-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclooctylamino)-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-42-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(bicyclo[2.2.1]hept-2-ylamino)-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-43-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(trans-4-hydroxycyclohexyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 643089-44-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2-hydroxycyclohexyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-45-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-46-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[1-(phenylmethyl)-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643089-47-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[[(3S)-1-(phenylmethyl)-3-pyrrolidiny]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643089-48-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-49-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2-methoxyethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-50-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(cyanomethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-51-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(1-ethyl-2-pyrrolidinyl)methyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-52'-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-(2-propenylamino)- (9CI) (CA INDEX NAME)




RN 643089-53-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-(2-propenylamino)- (9CI) (CA INDEX NAME)





RN 643089-54-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[tetrahydro-2-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-55-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2-hydroxy-1,1-dimethylethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-56-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[(2,2,2-trifluoroethyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-57-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(cyclopropylmethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)





RN 643089-58-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 643089-59-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(1-methyl-1-phenylethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-60-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[[(1R)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643089-61-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-[[(1S)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643089-62-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[(1S)-2-hydroxy-1-phenylethyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643089-63-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[(1R)-2-hydroxy-1-phenylethyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/518,043



RN 643089-64-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(1R)-1-cyclohexylethyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643089-65-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[[(1S)-1-cyclohexylethyl]amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643089-66-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2-hydroxy-1-methylethyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-67-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(2-hydroxypropyl)amino]-2-[[4-(4-morpholinylmethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-68-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(trans-4-hydroxycyclohexyl)amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 643089-69-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643089-70-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]- (9CI) (CA INDEX NAME)





RN 643089-71-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2,3-dihydro-1H-inden-1-yl)amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-72-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(1-methyl-1-phenylethyl)amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-73-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[1-(2-fluorophenyl)ethyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-74-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[1-(2-fluorophenyl)-2-hydroxyethyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-75-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[4-(4-morpholinyl)phenyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 643089-76-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-77-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[(2,2,2-trifluoroethyl)amino]- (9CI) (CA INDEX NAME)



RN 643089-78-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[{(1S)-2-hydroxy-1-phenylethyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643089-79-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[[(1R)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643089-80-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-morpholinyl)phenyl]amino]-4-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-81-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3-(1-hydroxyethyl)phenyl]amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-82-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(2-hydroxyethyl)phenyl]amino]-4-(1H-indol-5-ylamino)- (9CI) (CA INDEX NAME)




RN 643089-83-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3,5-difluorophenyl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-84-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(2,5-difluorophenyl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-85-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(2,6-difluorophenyl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

10/518,043




RN 643089-86-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3,4-difluorophenyl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-87-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2,4-difluorophenyl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643089-88-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[4-[(methylsulfonyl)amino]methyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643089-89-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[[[(2-hydroxyethyl)amino]methyl]phenyl]amino]-4-[(3-methylphenyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 643089-90-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(1-aminoethyl)phenyl]amino]-4-[(3-methylphenyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 643089-91-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(hydroxymethyl)phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-92-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-hydroxyphenyl)amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-93-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4'-hydroxy[1,1'-biphenyl]-4-yl)amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-94-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-ethylphenyl)amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-95-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(diethylamino)carbonyl]phenyl]amino]-4-[(3-methylphenyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 643089-96-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(dimethylamino)methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643089-97-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(2-hydroxyethyl)phenyl]amino]-4-

10/518,043


[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 643089-98-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[(4-hydroxy-1-piperidiny)methyl]phenyl]amino]-4-[(3-methylphenyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 643089-99-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-cyanophenyl)amino]-2-[[4-[(4-hydroxy-1-piperidiny)methyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-00-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[[[(2-hydroxyethyl)methylamino]methyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643090-01-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-02-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[[methyl(2-phenylethyl)amino]methyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-03-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[(cyclohexylmethylamino)methyl]phenyl]amino]-4-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 643090-04-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[2-hydroxy-1-(hydroxymethyl)ethyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-05-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(3-hydroxypropyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-06-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(3-ethylphenyl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-07-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


10/518,043



● HCl


RN 643090-08-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-cyanophenyl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-09-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(2-hydroxyethyl)phenyl]amino]-4-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



10/518,043


RN 643090-10-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-2-[[4-(2-hydroxyethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-11-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(2-hydroxy-1,1-dimethylethyl)phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-12-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(2-methoxyethyl)phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-13-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(2-hydroxy-1,1-dimethylethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-14-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-[(trans-4-hydroxycyclohexyl)amino]phenyl]amino]-4-[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 643090-15-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(dimethylamino)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-16-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(diethylamino)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-17-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(methylthio)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-18-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(acetylamino)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-19-1 CAPLUS

CN Benzeneacetic acid, 4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 643090-20-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(cyanomethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-21-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-22-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-hydroxyphenyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-23-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(methylsulfonyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-24-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-acetylphenyl)amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-25-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-butoxyphenyl)amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-26-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[4-[(4-aminophenyl)thio]phenyl]amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-27-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]-4-[[4-((2,3,6-trifluorophenyl)methyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-28-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(phenylamino)phenyl]amino]-4-[[4-((2,3,6-trifluorophenyl)methyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-29-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[ethyl(1-methylethyl)amino]phenyl]amino]-4-[[4-((2,3,6-trifluorophenyl)methyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-30-6 CAPLUS


CN Carbamic acid, [4-[[5-(aminocarbonyl)-4-[[2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 643090-31-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[4-(1H-pyrazol-1-ylmethyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

10/518,043




RN 643090-32-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(acetylethylamino)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-33-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-ethoxyphenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-34-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-35-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[3-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-36-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-4-(2-hydroxyethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-37-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-38-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-4-[[[(1R)-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643090-39-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-4-[[[(1S)-2-hydroxy-1-phenylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 643090-40-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-41-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-acetylphenyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-42-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-hydroxyphenyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-43-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(hydroxymethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-44-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(methylthio)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-45-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-hydroxyphenyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-46-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-[(diethylamino)methyl]-4-hydroxyphenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-47-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-methoxyphenyl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-48-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-[(butylamino)sulfonyl]phenyl]amino]-4-[[2,3,6-trifluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



IT 643090-49-7P 643090-50-0P 643090-51-1P
 643090-52-2P 643090-53-3P 643090-54-4P
 643090-56-6P 643090-57-7P 643090-58-8P
 643090-59-9P 643090-61-3P 643090-63-5P
 643090-64-6P 643090-65-7P 643090-66-8P
 643090-67-9P 643090-68-0P 643090-69-1P
 643090-70-4P 643090-71-5P 643090-72-6P
 643090-73-7P 643090-74-8P 643090-75-9P
 643090-76-0P 643090-77-1P 643090-78-2P
 643090-80-6P 643090-81-7P 643090-82-8P
 643090-83-9P 643090-84-0P 643090-85-1P
 643736-06-5P 644996-28-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal transducer and activator of transcription (STAT6), Th2 cell

10/518,043

differentiation inhibitors, and preventives and/therapeutics for
respiratory diseases)


RN 643090-49-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-fluoro-4-methoxyphenyl)amino]-4-[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-50-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-(1-hydroxyethyl)phenyl]amino]-4-[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-51-1 CAPLUS

CN Carbamic acid, [3-[[5-(aminocarbonyl)-4-[[(2,3,6-trifluorophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 643090-52-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-hydroxy-3-(hydroxymethyl)phenyl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-53-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(dimethylamino)methyl]phenyl]amino]-N-methyl-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-54-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-56-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-fluoro-4-(2-hydroxyethyl)phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-57-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-2-[(2,3-dihydro-1-methyl-1H-indol-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 643090-58-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-methyl-1H-indol-5-yl)amino]-4-
[[(2-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 643090-59-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-1-
methyl-6-quinoliny]amino]- (9CI) (CA INDEX NAME)

RN 643090-61-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-
methyl-7-isoquinoliny]amino]- (9CI) (CA INDEX NAME)


RN 643090-63-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-methyl-1H-indol-5-yl)amino]-4-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-64-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-methyl-1H-indol-6-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-65-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-1-methyl-7-quinolinyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-66-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1-methyl-1H-indol-5-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-67-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(1-acetyl-2,3-dihydro-1H-indol-5-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-68-0 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-(6-quinolinylamino)-
 (9CI) (CA INDEX NAME)




RN 643090-69-1 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-(1H-indol-5-ylamino)-4-[(phenylmethyl)amino]-
 (9CI) (CA INDEX NAME)



RN 643090-70-4 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-(1H-indazol-5-ylamino)-4-[(phenylmethyl)amino]-
 (9CI) (CA INDEX NAME)




RN 643090-71-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-(1H-indazol-6-ylamino)-4-[(phenylmethyl)amino]-
 (9CI) (CA INDEX NAME)




RN 643090-72-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-73-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(6-methoxy-3-pyridinyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-74-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-1-oxo-6-isoquinolinyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 643090-75-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[6-(4-morpholinyl)-3-pyridinyl]amino]-4-

10/518,043


[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643090-76-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643090-77-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-1-oxo-7-isoquinolinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 643090-78-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


10/518,043



● HCl


RN 643090-80-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-methyl-1H-indol-5-yl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-81-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(6-benzothiazolylamino)-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-82-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-83-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-oxo-2H-1-benzopyran-6-yl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-84-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(trifluoromethyl)-1H-benzimidazol-5-yl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-85-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(1-methyl-1H-indol-5-yl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643736-06-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[(3S)-5-oxo-3-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 644996-28-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3,4-dimethoxyphenyl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



IT 643087-45-0 643087-46-1 643087-47-2


643087-48-3 643087-56-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal transducer and activator of transcription (STAT6), Th2 cell differentiation inhibitors, and preventives and/therapeutics for respiratory diseases)

RN 643087-45-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-[[5-(aminocarbonyl)-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, 1,1-dimethylethyl

ester (9CI) (CA INDEX NAME)




RN 643087-46-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[[4-(1-piperidin-1-yloxy)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643087-47-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[2-fluoro-6-(phenylmethoxy)phenyl]methyl]amino]-2-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 643087-48-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[2-(aminomethyl)-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643087-56-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(aminomethyl)phenyl]amino]-4-[(3-methylphenyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 643087-06-3P 643087-49-4P 643087-59-6P


643087-60-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal transducer and activator of transcription (STAT6), Th2 cell differentiation inhibitors, and preventives and/therapeutics for respiratory diseases)


RN 643087-06-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(aminomethyl)phenyl]amino]-N-methyl-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-49-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[2-[(methylamino)methyl]-4-morpholinyl]phenyl]amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643087-59-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[4-[[trifluoroacetyl]amino]methyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 643087-60-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[[4-[[methyl(trifluoroacetyl)amino]methyl]phenyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:51442 CAPLUS
 DN 136:102398
 TI Preparation of 4-amino-2-anilino-5-cyanopyrimidines as antitumor agents
 IN Thomas, Andrew Peter; Newcombe, Nicholas John; Heaton, David William
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004429	A1	20020117	WO 2001-GB3084	20010706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2415486	A1	20020117	CA 2001-2415486	20010706
	EP 1303496	A1	20030423	EP 2001-947671	20010706
	EP 1303496	B1	20070912		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012420	A	20030624	BR 2001-12420	20010706
	HU 200301722	A2	20031229	HU 2003-1722	20010706
	JP 2004502763	T	20040129	JP 2002-509296	20010706
	NZ 523357	A	20040730	NZ 2001-523357	20010706
	EE 200300020	A	20041015	EE 2003-20	20010706
	RU 2299201	C2	20070520	RU 2003-103848	20010706
	TW 221470	B	20041001	TW 2001-90116869	20010710
	ZA 2003000079	A	20040505	ZA 2003-79	20030103
	IN 2003MN00029	A	20050204	IN 2003-MN29	20030106
	US 2003216406	A1	20031120	US 2003-332275	20030107
	US 6908920	B2	20050621		
	BG 107451	A	20030930	BG 2003-107451	20030108
	MX 2003PA00254	A	20041213	MX 2003-PA254	20030109
	NO 2003000146	A	20030110	NO 2003-146	20030110
PRAI	GB 2000-16877	A	20000711		
	WO 2001-GB3084	W	20010706		
OS	MARPAT 136:102398				

AB The title compds. [I; R1 = halo, NO2, CN, etc.; p = 0-4; R2 = sulfamoyl, EB; q = 0-2; p + q = 1-5; R3 = H, alkyl, alkenyl, etc.; R4 = alkyl, alkenyl, alkynyl, etc.; or NR3R4 = (un)substituted heterocyclyl such morpholino; B = alkyl, alkenyl, Ph, etc.; E = CO, NHCO, CONH, etc.], useful as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, were prepared Thus, reacting 2-chloro-5-cyano-4-morpholinopyrimidine with 4-[N-(3-isopropylaminopropyl)sulfamoyl]aniline in the presence of 1N HCl in 2-butanol afforded 19% I [R2 = 4-[N-(3-isopropylaminopropyl)sulfamoyl]; R1 = H; NR3R4 = morpholino] which showed IC50 of 0.148 μ M against CDK2. The title compds. I showed IC50's in the range 1 μ M to 1 nM when tested in assay measuring inhibition of cell growth.

IT 389606-23-9P 389606-24-0P 389606-26-2P
 389606-27-3P 389606-28-4P 389606-29-5P

The disclosed compds with -CO-N (carbamide) groups are Int. in the reference

Did not use in the Ref

Further claim 1 requires a -N-SO2- attachment and does not indicate a -SO2-N- attach


389606-30-8P 389606-33-1P 389606-34-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-amino-2-anilino-5-cyanopyrimidines as antitumor agents)


RN 389606-23-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(butylamino)-N-(1,1-dimethylethyl)-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389606-24-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(1,1-dimethylethyl)-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]-4-[(2,2,2-trifluoroethyl)amino]- (9CI) (CA INDEX NAME)




RN 389606-26-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclopropylamino)-N-(1,1-dimethylethyl)-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)





RN 389606-27-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(cyclopropylmethyl)amino]-N-(1,1-dimethylethyl)-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389606-28-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(cyclohexylamino)-N-(1,1-dimethylethyl)-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389606-29-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(1,1-dimethylethyl)-4-[[[(tetrahydro-2-furanyl)methyl]amino]-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389606-30-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(1,1-dimethylethyl)-4-[(3-pyridinylmethyl)amino]-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389606-33-1 CAPLUS

CN Glycine, N-[5-[[[(1,1-dimethylethyl)amino]carbonyl]-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]-, butyl ester (9CI) (CA INDEX NAME)



RN 389606-34-2 CAPLUS

CN β -Alanine, N-[5-[[[(1,1-dimethylethyl)amino]carbonyl]-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:833290 CAPLUS
 DN 135:371765

TI Preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors

IN Kukla, Michael Joseph; Ludovici, Donald William; Kavash, Robert W.; De Corte, Bart Lieven Daniel; Heeres, Jan; Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; De Jonge, Marc Rene; Van Aken Koen, Jeanne Alfons; Krief, Alain; Leenders, Ruben Gerardus George

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085700	A2	20011115	WO 2001-EP4991	20010503
	WO 2001085700	A3	20020207		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2406562	A1	20011115	CA 2001-2406562	20010503
	EP 1282606	A2	20030212	EP 2001-929616	20010503
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003535828	T	20031202	JP 2001-582301	20010503
	AU 783981	B2	20060112	AU 2001-56333	20010503
	US 2003171374	A1	20030911	US 2002-275931	20021108
PRAI	US 2000-202472P	P	20000508		
	WO 2001-EP4991	W	20010503		

OS MARPAT 135:371765

AB The title compds. [I; a1:a2a3:a4 = CH:CHCH:CH, N:CHCH:CH; N:CHN:CH, N:CHCH:N, N:NCH:CH; n = 0-5; R1 = H, aryl, formyl, etc.; R2 = OH, halo, alkyl, etc.; L = alkyl, alkenyl, cycloalkyl, etc.; Q = CN, OH, SH, etc.; Z = CY, N; Y = H, OH, halo, etc.; provided that when Q = halo then Z = N; or when Q = polyhaloalkyl then Y = H or alkyl] were prepared Thus, reacting 4-(4-chloro-6-methoxymethylpyrimidin-2-ylamino)benzonitrile (preparation given) with 4-hydroxy-3,5-dimethylbenzonitrile afforded II which showed IC50 of 0.001585 μ M against HIV in MT-4 cell line.


IT 373686-66-9P 373686-73-8P 373686-80-7P
 373687-60-6P 373687-74-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors)

RN 373686-66-9 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-6-[(2,4,6-trimethylphenyl)amino]- (9CI) (CA INDEX NAME)

10/518,043




RN 373686-73-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-N-methyl-6-[(2,4,6-trimethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 373686-80-7 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-N,N-dimethyl-6-[(2,4,6-trimethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 373687-60-6 CAPLUS


CN 4-Pyrimidinecarboxamide, 2-[(6-methoxy-3-pyridinyl)amino]-6-[(2,4,6-trimethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 373687-74-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 5-bromo-2-[(4-cyanophenyl)amino]-6-[(2,4,6-trimethylphenyl)amino]- (9CI) (CA INDEX NAME)

← -CONH₂ is
at 4-position
as compared to 5-position
in the claims.
* Not applicable to
claims 3-6.



L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:816647 CAPLUS
 DN 135:357948
 TI Preparation of heterocyclic compounds as phosphodiesterase V (PDE V) inhibitors
 IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohel
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO PCT Int. Appl., 207 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 200141142	A	20011112	AU 2001-41142	20010315
	CA 2407231	A1	20021023	CA 2001-2407231	20010315
	EP 1277741	A1	20030122	EP 2001-912373	20010315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 522217	A	20040430	NZ 2001-522217	20010315
	CN 1657523	A	20050824	CN 2004-10098098	20010315
	US 2003229089	A1	20031211	US 2002-258545	20021025
	US 7220736	B2	20070522		
	MX 2002PA10693	A	20030310	MX 2002-PA10693	20021028
	US 2004142930	A1	20040722	US 2003-699804	20031104
	AU 2005203687	A1	20050908	AU 2005-203687	20050817
PRAI	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	AU 2001-41142	A3	20010315		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		

OS MARPAT 135:357948

AB Comps. of the general formula (I) or pharmacol. acceptable salts thereof [wherein X is :CH or N; Y is NH, NR₄, S, O, CH:N, N:CH, N:N, CH:CH, or the like; R₁ is lower alkoxy, amino, a nitrogenous heterocyclic group, or a hydroxyl group substituted with a heterocyclic group (wherein each group may be substituted); R₂ is either a lower alkylamino or lower alkoxy group which may be substituted with aryl, or a lower alkoxy group substituted with a nitrogenous aromatic heterocyclic group; and R₃ is aryl, a nitrogenous heterocyclic group, lower alkyl, lower alkoxy, lower cycloalkoxy, a hydroxyl group substituted with a nitrogenous heterocyclic group, or amino (wherein each group may be substituted), or alternatively, R₃ and the substituent of Y may be united to form a lactone ring] or pharmacol. acceptable salts thereof are prepared These comps. exhibit excellent PDE V inhibitory activity and are useful as preventive or therapeutic agents for various diseases due to dysfunction of the signal transduction through cGMP, in particular impotence, pulmonary hypertension, and diabetic renal failure paralysis (no data). Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF at room temperature for 30 min and then condensed with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-

methoxybenzylamino)pyrimidine (preparation given) in THF at room temperature for 1 h


to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.

IT 372115-17-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as phosphodiesterase V inhibitors preventive or therapeutic agents for various diseases due to dysfunction of signal transduction through cGMP)

RN 372115-17-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[(phenylmethyl)amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



*is 0 of 2
in ~~the~~ claims 1, 3, 4, 5, 6.
at the most a
103!*

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:900621 CAPLUS
 DN 134:56683
 TI Preparation of nitrogen-containing heterocyclic derivatives as remedies
 for complications of diabetes based on protein kinase C inhibition
 IN Suzuki, Takayuki; Onda, Kenichi; Murakami, Takeshi; Negoro, Kenji; Yahiro,
 Kiyoshi; Maruyama, Tatsuya; Shimaya, Akiyoshi; Ohta, Mitsuaki
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076980	A1	20001221	WO 2000-JP3768	20000609
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	JP 1999-163344	A	19990610		
	JP 1999-165217	A	19990611		

OS MARPAT 134:56683


AB The title compds. I [Y and X together are N:N, C(R4):N, etc.; D = (un)substituted aryl, etc.; R1 = (un)substituted heteroaryl, etc.; A1, A2 = (un)substituted alkylene, etc.; R2, R3, R4 = H, OH, etc.; or R1A2NR3 = (un)substituted heteroaryl] are prepared The title compound II in vitro showed IC50 of 0.0049 μ mol against protein kinase C.

IT 313338-17-9P 313338-52-2P 313338-54-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of nitrogen-containing heterocyclic derivs. as remedies for complications of diabetes)

RN 313338-17-9 CAPLUS


CN Carbamic acid, [2-[3-[[5-(aminocarbonyl)-1,4-dihydro-6-[(3-methylphenyl)amino]-4-oxo-2-pyrimidinyl]amino]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 313338-52-2 CAPLUS
 CN 5-Pyrimidinecarboxamide, 1,4-dihydro-2-[[3-[2-(methyamino)ethyl]phenyl]amino]-6-[(3-methylphenyl)amino]-4-oxo- (9CI)
 (CA INDEX NAME)



RN 313338-54-4 CAPLUS
 CN 5-Pyrimidinecarboxamide, 2-[[3-[2-(dimethylamino)ethyl]phenyl]amino]-1,4-dihydro-6-[(3-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:457043 CAPLUS
 DN 133:89537
 TI Preparation of 2,4-pyrimidinediamine derivatives as anticancer agents
 IN Bradbury, Robert Hugh; Breault, Gloria Anne; Jewsbury, Philip John; Pease, Janet Elizabeth
 PA Astrazeneca UK Limited, UK
 SO PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039101	A1	20000706	WO 1999-GB4325	19991220
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2352896	A1	20000706	CA 1999-2352896	19991220
	EP 1140860	A1	20011010	EP 1999-962375	19991220
	EP 1140860	B1	20040922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9916590	A	20011023	BR 1999-16590	19991220
	JP 2002533446	T	20021008	JP 2000-591012	19991220
	AU 763091	B2	20030710	AU 2000-18743	19991220
	NZ 512118	A	20030829	NZ 1999-512118	19991220
	AT 277020	T	20041015	AT 1999-962375	19991220
	PT 1140860	T	20050131	PT 1999-962375	19991220
	ES 2228145	T3	20050401	ES 1999-962375	19991220
	ZA 2001004413	A	20020829	ZA 2001-4413	20010529
	NO 2001003038	A	20010822	NO 2001-3038	20010619
	NO 319815	B1	20050919		
	MX 2001PA06575	A	20011203	MX 2001-PA6575	20010625
	US 6593326	B1	20030715	US 2001-868602	20010823
PRAI	GB 1998-28511	A	19981224		
	WO 1999-GB4325	W	19991220		
OS	MARPAT 133:89537				

AB The present invention relates to the title compds. (I) [wherein R1 = H, (un)substituted alkyl, alkenyl, or alkynyl, benzyl, 2-phenylethyl, phthalimidoalkyl, or cycloalkylalkyl; Rx = halo, OH, NO2, NH2, CN, SH, CO2H, SO2NH2, NHCHO, ureido, etc.; Q1 and Q2 = independently (un)substituted aryl, 5- or 6-membered monocycle, or 9- or 10-membered bicyclic heterocycle], processes for their manufacture, and pharmaceutical compns. containing them. For example, addition of 4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline•HCl in MeOH to 5-bromo-2-chloro-4-(indan-5-ylamino)pyrimidine in BuOH (preps. given) and heating to 100°C for 18 h gave II (42%). I inhibited the effects of cyclin-dependent serine/threonine kinases (CDKs), showing selectivity for CDK2 (no data), CDK4 (IC50 ranging from 0.02 µM to 0.07 µM), and CDK6 (no data). In a tyrosine kinase activity assay using Sf21 cells transfected with plaque-pure FAK recombinant virus, I also inhibited focal adhesion kinase 3 (FAK3) with IC50 ranging from 0.032 µM to 0.07 µM. Typical IC50 values for I when tested for inhibition of cell growth in an Sulforhodamine B (SRB) assay were in the range of 1 mM to 1 nM. Thus, I


possess anti-cancer properties, including anti-cell-migration, antiproliferation and/or apoptotic properties. Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumors and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases, and ocular diseases with retinal vessel proliferation.

IT 280578-87-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-pyrimidinediamine anticancer agents by coupling halopyrimidines with anilines and optional derivatization)

RN 280578-87-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]amino]-N-(1-methylethyl)-4-(phenylamino)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:404941 CAPLUS

DN 131:44844

TI preparation of novel pyrimidine-5-carboxamide derivatives as tyrosinase inhibitors

IN Hisamichi, Hiroyuki; Naito, Ryo; Kawazoe, Souichirou; Toyoshima, Akira; Tanabe, Kazuhito; Nakai, Eiichi; Ichikawa, Atsushi; Orita, Akiko; Takeuchi, Makoto

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2 .

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9931073	A1	19990624	WO 1998-JP5643	19981214
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9915071	A	19990705	AU 1999-15071	19981214
	EP 1054004	A1	20001122	EP 1998-959197	19981214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	US 6432963	B1	20020813	US 2000-581595	20000615
PRAI	JP 1997-344588	A	19971215		
	WO 1998-JP5643	W	19981214		

OS MARPAT 131:44844


AB Pyrimidine-5-carboxamide derivs. or salts [I; X = O, S, NR1, CO, NR1CO, CONR1, C=NOR1, a bond; Y = lower alkylene optionally substituted by OR1 or NHR1, a bond; Z = O, NR2, a bond; A = H, optionally substituted lower alkyl, lower alkyl optionally having CO, optionally substituted aryl or heteroaryl, optionally substituted cycloalkyl, optionally substituted and saturated N heterocycle; B = optionally substituted aryl or heteroaryl; R1, R2 = H or lower alkyl optionally containing CO], effective tyrosinase inhibitors useful as 5-HT antagonists, antiallergics, were prepared I showed IC50 < 0.1 µM in scintillation proximity assay. I were effective at 0.1-10 mg/kg-day p.o.

IT 227449-92-5P 227450-06-8P 227450-13-7P
227450-14-8P 227450-22-8P 227450-24-0P
227450-27-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel pyrimidine-5-carboxamide derivs. as tyrosinase inhibitors)


RN 227449-92-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(aminomethyl)phenyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 227450-06-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-aminophenyl)methyl]amino]-4-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 227450-13-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-aminophenyl)methyl]amino]-4-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 227450-14-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-hydroxyphenyl)amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 227450-22-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-[(3-methylphenyl)amino]- (CA INDEX NAME)




RN 227450-24-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-4-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 227450-27-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(3-methylphenyl)amino]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




IT 227449-47-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel pyrimidine-5-carboxamide derivs. as tyrosinase inhibitors)

RN 227449-47-0 CAPLUS


CN Carbamic acid, [[4-[[5-(aminocarbonyl)-4-[(3-methylphenyl)amino]-2-pyrimidinyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1976:432948 CAPLUS
 DN 85:32948
 TI Synthesis of 2,4-disubstituted 5-aminopyrimidine-6-carboxylic acids derivatives. Part I.
 AU Machon, Zdzislaw; Jasztold-Howorko, Ryszard
 CS Inst. Chem. Technol. Drugs, Med. Acad., Wroclaw, Pol.
 SO Polish Journal of Pharmacology and Pharmacy (1976), 28(1), 61-7
 CODEN: PJPPAA; ISSN: 0301-0244
 DT Journal
 LA English
 AB Pyrimidinecarboxylic acid derivs. I (R = R1 = NH2, NEt2, NHPH, cyclohexylamino, NHC6H4Cl-4, NHC6H4OEt-4; R = NEt2, NHPH, cyclohexylamino, NHC6H4OEt-4, R1 = OEt; R = NHC6H4OEt-4, R1 = OH) were prepared by N-benzoylating 5-aminoorotic acid, treating the N-benzoyl derivative with POCl3, treating the lactam II with NaOH, EtOH, or amines to give I (R = Cl, R1 = OH, OEt, R = R1 = amino resp.) and treating I (R = Cl) with amines. None of the products showed any antiinflammatory or virucidal acitivity.
 IT 59662-96-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 59662-96-3 CAPLUS
 CN 4-Pyrimidinecarboxamide, 5-(benzoylamino)-N-phenyl-2,6-bis(phenylamino)-
 (9CI) (CA INDEX NAME)



only one
 — NH
 sub:
 in the
 claimed str.

L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1961:33107 CAPLUS
 DN 55:33107
 OREF 55:6489c-i,6490a-i,6491a-c
 TI Pyrimido[4,5-d]pyrimidines. I
 AU Taylor, Edward C., Jr.; Knopf, R. J.; Meyer, R. F.; Holmes, Ann; Hoefle, M. L.
 CS Parke Davis and Co., Detroit, MI
 SO Journal of the American Chemical Society (1960), 82, 5711-18
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA Unavailable
 OS CASREACT 55:33107
 AB A number of pyrimido[4,5-d]pyrimidines were prepared as potential diuretic agents. NaOMe (10.8 g.) in 200 cc. absolute EtOH and 50 g. O-methylisourea p-toluenesulfonate stirred 15 min., treated with 24.4 g. EtOCH:C(CN)₂ in 2-g. portions, the mixture stirred 1 hr. at room temperature, refluxed 1 hr., cooled, filtered, and the residue repptd. from 100 cc. cold 2N HCl with concentrated NH₄OH gave 2-methoxy-4-amino-5-cyanopyrimidine, m. 221-2° (EtOH). Formamidine-HCl (8.05 g.) and 2.5 g. Na in 100 cc. absolute EtOH stirred 15 min. at room temperature, filtered, treated with 13.6 g. methylethoxymethylenemalononitrile (I), the mixture heated 10 min. on the steam bath, and cooled gave 8.4 g. 4-amino-5-cyano-6-methylpyrimidine (II), m. 217-19° (EtOH). (H₂N)₂CS (7.6 g.) added to 2.5 g. Na in 100 cc. absolute EtOH, the mixture warmed to solution, cooled to 40°, treated with stirring with 13.6 g. I in small portions, heated 1 hr. on the steam bath, cooled, the precipitated Na salt dissolved in 200 cc. H₂O, treated with stirring with 10 g. MeI, and filtered gave 9.4 g. 2-MeS derivative of II, pale yellow needles, m. 238-40° (EtOH). 2-Ethylthio-4-amino-5-cyanopyrimidine (III) (54.0 g.) in 177 g. PrNH₂ refluxed 18 hrs. and evaporated gave 40.2 g. 2-propylamino-4-amino-5-cyanopyrimidine, m. 167-9° (EtOH). III (10.0 g.), 25 cc. 25% aqueous MeNH₂, and 40 cc. EtOH heated 3 hrs. in an autoclave at 130° and cooled yielded 5.7 g. 2-methylamino-4-amino-5-cyanopyrimidine (IV). III (20.0 g.), 50 cc. PhNH₂, and 2 drops concentrated HCl heated 3 hrs. at 150° and 1 hr. at 175°, cooled, suspended in 150 cc. EtOH, and filtered gave 17.3 g. 2-PhNH analog of IV, yellow solid, m. 234-5°. Similarly were prepared the following 2-substituted-4-amino-4-cyanopyrimidines (2-substituent, % yield, and m.p. given): piperidino, 25, 212-13°; 4-methylpiperazino, 49, 179°; CH₂:CHCH₂NH, 43, 171-2°; Me₂NCH₂CH₂NH, 55, 179-80°; C₆H₁₃NH, 44, 134-5°; cyclohexylamino, 53, 182-3°; PhCH₂NH, 57, 177-9°; o-ClC₆H₄CH₂NH, 40, 185-7°. All the compds. were recrystd. from EtOH. IV (12.5 g.) added in portions below 30° to 40 cc. concentrated H₂SO₄, the mixt kept 2 hrs. at room temperature, poured into 150 g. crushed ice, filtered, the residue dissolved in 150 cc. boiling H₂O, and neutralized with concentrated NH₄OH gave 9.6 g. 2-methylamino-4-aminopyrimidine-5-carboxamide (V), m. 268-70°. Similarly were prepared the following 2-substituted-4-aminopyrimidine-5-carboxamides (2-substituent, % yield, and m.p. given): C₆H₁₃NH, 88°, 155° (EtOH); PhCH₂NH, 62, 180-1° (EtOH); o-ClC₆H₄CH₂NH, 71, 196-8° (EtOH); Me₂N, 76, 289-90° (H₂O); PhNH, 89, 246-7° (H₂O); 4-methylpiperazino, 65, 222-3° (H₂O). 2,4-Diamino-6-methylpyrimidine-5-carboxamide, 74%, m. 240-1° (H₂O). 2-Ethylthio-4-aminopyrimidine-5-carboxamide (20 g.) and 35 cc. H₂NCH₂CH₂OH heated 4 hrs. at 110-15°, diluted with 100 cc. H₂O, cooled, and filtered gave 12.2 g. 2-(2-hydroxyethylamino)-4-aminopyrimidine-5-carboxamide, m. 230° (H₂O). 2,4-Diamino-5-cyanopyrimidine (VI) (27 g.) and 100 g. HCONH₂ refluxed 0.5 hr., cooled, diluted with 100 cc. EtOH,


filtered, the residue dissolved in 400 cc. hot N HCl, and repptd. with concentrated NH₄OH gave 15.1 g. 2,5-diaminopyrimido[4,5-d]pyrimidine-H₂O, light tan, m. above 300°. Similarly were prepared 5-aminopyrimido[4,5-d]pyrimidine (VII), 16%, m. above 360° (sublimed), and the following 2-substituted derivs. of VII (2-substituent, % yield, and m.p. given): Ph, 25, above 300° (EtOH); 4-methylpiperazino, 70, above 300° (EtOH); piperidino, 29, above 300° (EtOH); Me₂NHCl.H₂O, 58, above 300° (H₂O); PhCH₂NH, 7, 285-7° (EtOH); C₆H₁₃NH, 23, 276-8° (EtOH); MeS, 19, above 300° (sublimed). H₂NC(:NH)NH₂.HCl (VIII) (9.6 g.), 13.5 g. VI, and 5.4 g. NaOMe in 200 cc. Ethyl Cellosolve refluxed 20 hrs. with stirring, filtered, the crude residue (16.5 g.) washed with 100 cc. warm H₂O, and recrystd. from 600 cc. H₂O containing 20 cc. concentrated HCl gave 9.1 g. 2,4,7-triaminopyrimido[4,5-d]pyrimidine, m. above 300°. Similarly were prepared the following 7-substituted derivs. of 2,4-diaminopyrimido[4,5-d]pyrimidine (7-substituent, % yield, and m.p. given): H, 78, above 300° (H₂O); MeNH.HCl.0.5H₂O, 35, above 300° (H₂O); PrNH, 92, 309-10° (EtOH); C₆H₁₃NH, 72, 272-3° (EtOH); HOCH₂CH₂NH, 33, above 300° (H₂O); Me₂N, 61, above 300° (EtOH); piperidino, 50, above 300° (Ethyl Cellosolve); (HOCH₂CH₂)₂N, 74, 285° (EtOH); PhCH₂NH, 73, 294-5° (EtOH); PhNH, 78, above 300°; H₂NNH, 88, above 300° (H₂O); EtS, 40, above 300° (Ethyl Cellosolve); Ph, 94, above 300° (Ethyl Cellosolve); Me, 74, above 300° (H₂O). PhC(:NH)NH₂.HCl (15.5 g.) and 18.0 g. III refluxed 24 hrs. with stirring with 5.4 g. NaOMe in 200 cc. absolute EtOH, refluxed 24 hrs. with stirring, filtered hot, evaporated, and the residual gum treated with 100 cc. H₂O gave 4.6 g. 2-phenyl-4-amino-7-ethylthiopyrimido[4,5-d]pyrimidine (IX), m. 226-8° (EtOH). MeC(:NH)NH₂.HCl (9.5 g.) and 18.0 g. III refluxed 24 hrs. with 5.4 g. NaOMe in 200 cc. absolute EtOH gave similarly 5.5 g. 2-Me analog of IX, m. 279-80° (Ethyl Cellosolve). 2-Methylamino-4-aminopyrimidine-5-carboxamide (9.6 g.) and 25 cc. HCONH₂ refluxed 0.5 hr., cooled, diluted with 75 cc. EtOH, and filtered gave 5.7 g. 2-methylamino-5-hydroxypyrimido[4,5-d]pyrimidine, m. above 300° (glacial AcOH). Similarly were prepared the following 2-substituted-5-hydroxypyrimido[4,5-d]pyrimidines (2-substituent, % yield, and m.p. given): PrNH, 72, 295-6° (AcOH); CH₂:CHCH₂NH, 58, 278-80° (H₂O); Me₂N, 28, above 300° (AcOH); o-ClC₆H₄CH₂NH, 71, above 300° (AcOH); PhNH, 23, above 300° (AcOH). V (100 g.) in 500 cc. HC(OEt)₃ refluxed 3 hrs., concentrated, and cooled gave 81 g. 2-ethylthio-5-hydroxypyrimido[4,5-d]-pyrimidine, m. 244-6° (glacial AcOH). 2,4-Diaminopyrimidine-5-carboxamide (14.0 g.) and 100 cc. (EtCO)₂O refluxed 1 hr., cooled, and filtered gave 18 g. 2-ethyl-4-hydroxy-7-propionylaminopyrimido[4,5-d]pyrimidine (X). The X refluxed 1 hr. with 3.5 g. NaOH in 200 cc. H₂O, cooled, and filtered gave 9.5 g. 7-NH₂ analog (XI) of X, m. above 330° (glacial AcOH). Similarly was prepared with (PrCO)₂O the Pr analog of XI, 52%, m. above 300° (EtOH). In the same manner were prepared with Ac₂O the 2-Me analog (XII) of XI, 78%, m. above 300° (AcOH), the Am analog, 35%, m. 295-300° (50% aqueous EtOH), with (AmCO)₂O, and the 5-Me derivative of XII, 74%, m. above 300° (AcOH), with Ac₂O. In the same manner were prepared with Ac₂O the following 7-substituted 2-methyl-4-hydroxypyrimido[4,5-d]pyrimidines (7-substituent, % yield, and m.p. given): HOCH₂CH₂NH, 44, above 300° (H₂O); PrNH, 18, 294-5° (EtOH); C₆H₁₃NH, 23, 267-8° (EtOH); Me₂N, 26, 275-6° (EtOH); PhCH₂NH, 62, above 300° (AcOH); PhNH, 62, above 300° (EtOH); EtS, 75, 247-8° (EtOH); Me, 72, 310-15° (MeOH); MeS, 57, 288-90° (MeOH). Powdered VIII (30 g.) and 16.8 g. NaOMe in 200 cc. absolute EtOH stirred 0.5 hr. at room temperature, filtered, cooled to 5-10°, treated dropwise with 2-ethylthio-4-chloro-5-carbethoxypyrimidine, the mixture stirred 2 hrs. at room temperature, concentrated in vacuo, added to 150 cc. warm

H₂O, filtered, and neutralized with glacial AcOH gave 18.2 g. 2-amino-4-hydroxy-7-ethylthiopyrimido[4,5-d]pyrimidine (XIII), m. above 300° (glacial AcOH). XIII (5 g.) in 20 cc. 25% aqueous MeNH₂ and 30 cc. H₂O heated 4 hrs. in an autoclave at 140° and cooled gave 3.5 g. 7-MeNH analog of XIII, m. above 300°. 2-Benzylamino-5-hydroxypyrimido[4,5-d]pyrimidine (14.2 g.) and 13.6 g. P₂S₅ in 130 cc. C₅H₅N refluxed 4 hrs., cooled, and filtered gave 12.0 g. 2-benzylamino-5-mercaptopyrimido[4,5-d]pyrimidine (XIV), bright yellow, m. 290-1° (EtOH); the filtrate diluted with 200 cc. H₂O gave an addnl. 3.2 g. XIV. XIV (5 g.), 10 cc. PrNH₂, and 50 cc. EtOH heated 4 hrs. at 140° in an autoclave gave 1.7 g. 5-PrNH analog of XIV, m. 290-1° (EtOH). 2-Ethylthio-5-hydroxypyrimido[4,5-d]pyrimidine (XV) (100 g.), 110 g. P₂S₅, and 500 cc. C₅H₅N refluxed 3 hrs. with stirring, evaporated in vacuo, the residue dissolved in 1 l. 5% aqueous NaOH, and precipitated with AcOH gave 112 g. golden yellow 5-MeNH analog (XVI) of XV, m. 280-3° (EtOH). Similarly were prepared 2-methylthio-5-mercaptopyrimido[4,5-d]pyrimidine (XVII), 75%, m. 290-7° (C₅H₅N), and the 7-Me derivative (XVIII) of XVII, 28%, darkened at 260° (MeOH). XVI (12.5 g.) and 14 g. 25% aqueous MeNH₂ in 300 cc. H₂O refluxed 0.5 hr. and cooled gave 2.65 g. 2-ethylthio-5-methylaminopyrimido[4,5-d]pyrimidine (XIX), m. 275-80° (iso-PrOH). XIX (1 g.) and 30 cc. EtOH (saturated with NH₃) heated 5 hrs. at 135° in an autoclave gave 0.5 g. 2-amino-5-methylaminopyrimido[4,5-d]pyrimidine, m. above 330° (aqueous EtOH). XVIII (0.4 g.) and 15 cc. 7.5% aqueous Na₂CO₃ heated to 35-40°, treated with 0.5 cc. Me₂SO₄, stirred until homogeneous, and refrigerated overnight gave 0.32 g. 2,5-bis(methylthio)pyrimido[4,5-d]pyrimidine (XX), m. 183-5° (sublimed). XX (0.07 g.) in 8 cc. absolute EtOH stirred 15 hrs. at room temperature gave 0.075 g. 5-PhCH₂NH analog of XX, m. 278-80° (50% EtOH). By the same method as XIX were prepared the following 2,5-disubstituted-pyrimido[4,5-d]pyrimidines (2- and 5-substituents, % yield, and m.p. given): PhCH₂NH, CH₂:CHCH₂NH, 41, 274-5° (EtOH); EtS, PhCH₂NH, 35, 231-2° (iso-PrOH); EtSH, furfurylamino, 52, 219-20° (iso-PrOH); EtS, PhNH, 32, 250-5° (EtOH). With HC(OEt)₃ and Ac₂O was prepared 2-methylthio-5-hydroxypyrimido[4,5-d]pyrimidine, 72%, m. 225-9° (H₂O).

IT 99844-93-6P, 5-Pyrimidinecarboxamide, 4-amino-2-anilino-
104621-86-5P, 5-Pyrimidinecarboxamide, 4-amino-2-benzylamino-
104912-31-4P, 5-Pyrimidinecarboxamide, 4-amino-2-(o-chlorobenzylamino)-
RL: PREP (Preparation)
(preparation of)

RN 99844-93-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-amino-2-anilino- (6CI) (CA INDEX NAME)



RN 104621-86-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-amino-2-benzylamino- (6CI) (CA INDEX NAME)

10/518,043



RN 104912-31-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-amino-2-(o-chlorobenzylamino)- (6CI) (CA INDEX NAME)



10/518,043

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

101.07

275.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-14.82

-14.82

STN INTERNATIONAL LOGOFF AT 12:57:48 ON 20 SEP 2007